[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 189
1. Shimoyama T, Kimura B: [Peripheral intrapulmonary lipoma: report of a case]. Kyobu Geka; 2009 Dec;62(13):1186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest computed tomography showed a well-defined nodule of 1 cm diameter periphery in lower lobe of the right lung.
  • The differential diagnosis included benign lung tumors, such as intrapulmonary lymph nodes, granuloma etc.
  • To make diagnosis, a wedge resection of the pulmonary nodule was performed.
  • The tumor was diagnosed as a lipoma.
  • Although peripheral intrapulmonary lipoma is very rare, it should be kept in mind in the differential diagnosis of an intrapulmonary nodule.
  • [MeSH-major] Lipoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999101.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


2. Nishiguchi T, Mochizuki K, Nakayama T, Inoue Y, Ohata K, Wakasa K: A case of synovial sarcoma in the perivertebral space of the neck: clinical presentation, radiological findings and histopathological description. Br J Radiol; 2008 Mar;81(963):e72-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of synovial sarcoma in the neck that was initially considered to be a benign soft-tissue tumour.
  • The mass also encased the right vertebral artery and this suggested a malignant soft-tissue tumour.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Contrast Media. Diagnosis, Differential. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Lymph Nodes. Magnetic Resonance Imaging. Neck. Neurofibroma / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270287.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


3. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E: Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut; 2007 Jan;56(1):95-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical analysis of benign (n = 44 patients) and malignant (n = 69) pancreatic ductal cells showed significantly higher CapG staining intensity in nuclear (p<0.001) and cytoplasmic (p<0.001) compartments of malignant cells.
  • Similarly, gelsolin immunostaining of benign (n = 24 patients) and malignant (n = 68 patients) pancreatic ductal cells showed higher expression in both compartments (both p<0.001).
  • High nuclear CapG was associated with increased tumour size (p = 0.001).
  • [MeSH-major] Cell Movement / physiology. Gelsolin / analysis. Microfilament Proteins / analysis. Neoplasm Proteins / analysis. Nuclear Proteins / analysis. Pancreatic Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Line, Tumor. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Isomerism. Kaplan-Meier Estimate. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. RNA Interference / physiology. RNA, Neoplasm / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Dec 16;21(24):6781-90 [12485999.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1247-57 [12216092.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17945-52 [12637565.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):29136-44 [12754261.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6582-90 [14573680.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:14 [12605717.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):29-42 [15364130.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5283-92 [15454578.001]
  • [Cites] Nature. 1979 Oct 18;281(5732):583-6 [492320.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1413-5 [2255912.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1233-6 [1848726.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4106-12 [8382692.001]
  • [Cites] Cell Motil Cytoskeleton. 1993;26(3):227-38 [8293478.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):147-56 [7698981.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3228-32 [7614452.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1279-87 [9298983.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):322-7 [9443412.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):290-7 [9920419.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):47-57 [9921973.001]
  • [Cites] Prostate. 1999 Jun 15;40(1):14-9 [10344719.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2614-23 [15526166.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):611-22 [15548371.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3218-25 [15833853.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):665-78 [10684249.001]
  • [Cites] J Cell Biol. 2001 Aug 20;154(4):775-84 [11514591.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • (PMID = 16847067.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0301157; United States / NIGMS NIH HHS / GM / P50 GM021681; United States / NIGMS NIH HHS / GM / P05GM21681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 148412-71-9 / CAPG protein, human
  • [Other-IDs] NLM/ PMC1856675
  •  go-up   go-down


Advertisement
4. Gomard-Mennesson E, Isaac S, Freymond N, Guibert B, Pacheco Y, Devouassoux G: [Pulmonary metastases from Abrikossoff's tumour. Transformation capability of a benign granular cell tumour]. Rev Mal Respir; 2007 Sep;24(7):900-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from Abrikossoff's tumour. Transformation capability of a benign granular cell tumour].
  • [Transliterated title] Métastases pulmonaires d'une tumeur d'Abrikossoff. Transformation ou potentiel évolutif d'une tumeur bénigne à cellules granuleuses.
  • INTRODUCTION: Abrikossoff's tumour or granular cell tumour is usually benign involving multiple anatomical sites, most frequently the head, neck and airways.
  • CASE REPORT: We report the case of a mammary Abrikossoff's tumour, initially considered benign and treated solely by local surgery.
  • Seven years later the tumour was responsible for the development of sub-cutaneous and pulmonary metastases.
  • CONCLUSION: This original observation reports the case of a benign granular cell tumour that underwent malignant transformation after an interval of 7 years as indicated by the clinical progress and the cellular proliferation index Ki-67.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Granular Cell Tumor / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. S100 Proteins / analysis. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925675.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


5. Koenig AM, Quaas A, Ries T, Yekebas EF, Gawad KA, Vashist YK, Burdelski C, Mann O, Izbicki JR, Erbersdobler A: Perivascular epitheloid cell tumour (PEComa) of the retroperitoneum - a rare tumor with uncertain malignant behaviour: a case report. J Med Case Rep; 2009;3:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epitheloid cell tumour (PEComa) of the retroperitoneum - a rare tumor with uncertain malignant behaviour: a case report.
  • CASE PRESENTATION: Here we present the case of a cystic perivascular epitheloid cell tumour of the retroperitoneum associated with multifocal lung lesions.
  • The tumour displayed the typical morphological and immunohistochemical features of a perivascular epitheloid cell tumour.
  • Moreover, postoperative computed tomography scans demonstrated multiple lung lesions, which were radiologically interpreted as being most likely compatible with lymphangioleiomyomatosis.
  • CONCLUSION: Since lymphangioleiomyomatosis, an otherwise benign condition, belongs to the family of perivascular epitheloid cell tumours, it cannot be excluded that the lung lesions in this case in fact represent metastases from the retroperitoneal perivascular epitheloid cell tumour rather than independent neoplasms.
  • More experience with this new and unusual tumour entity is clearly needed in order to define reliable criteria for benign or malignant behaviour.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):837-40 [16498117.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Chest. 1999 Apr;115(4):1041-52 [10208206.001]
  • [Cites] Histopathology. 1998 Jul;33(1):91-3 [9726062.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1149-53 [8764751.001]
  • [Cites] Chest. 2000 Jan;117(1):25-30 [10631194.001]
  • [Cites] Chirurg. 1990 Apr;61(4):301-3 [2140768.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):563-8 [11406657.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):121-6 [11145246.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):1002-9 [10712355.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):307-8 [1599021.001]
  • (PMID = 19220895.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2649938
  •  go-up   go-down


6. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R: Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. Oral Oncol; 2008 Aug;44(8):743-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The oral region is an uncommon site for metastatic tumour cell colonization and is usually evidence of a wide spread disease.
  • The major primary sites presenting oral metastases were the lung, kidney, liver, and prostate for men, breast, female genital organs (FGO), kidney, and colo-rectum for women.
  • The primary site differs according to oral site colonization, in men the lung was the most common primary site affecting both the jawbones and oral mucosa (22% and 31.3%, respectively) followed by the prostate gland in the jawbones (11%) and kidney in the oral soft tissues (14%).
  • In women, the breast was the most common primary tumour affecting the jawbones and soft tissues (41% and 24.3%, respectively), followed by the adrenal and female genital organs (FGO) in the jawbones (7.7%) and FGO in the soft tissues (14.8%).
  • Because of its rarity, the diagnosis of a metastatic lesion in the oral region is challenging, both to the clinician and to the pathologist, in recognizing that a lesion is metastatic and in determining the site of origin.
  • The clinical presentation of a metastatic lesion in the oral cavity can be deceiving leading to a misdiagnosis of a benign process, therefore, in any case where the clinical presentation is unusual especially in patients with a known malignant disease a biopsy is mandatory.
  • [MeSH-minor] Adult. Case-Control Studies. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Sex Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061527.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 150
  •  go-up   go-down


7. Tischoff I, Tannapfel A: [Pathologic and anatomic evidence of peritoneal metastases]. Chirurg; 2007 Dec;78(12):1085-6, 1088-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Peritonealmetastasen in der pathologisch-anatomischen Befundung.
  • Ovarian carcinoma, colorectal cancer, and gastric cancer are the most frequent ones that show peritoneal involvement, along with carcinomas of the pancreas, gallbladder, uterus, and lung.
  • Primary tumours originating in the peritoneum such as malignant peritoneal mesothelioma, primary peritoneal carcinoma, and benign peritoneal tumours along with inflammatory and reactive lesions must be differentiated from peritoneal metastases.
  • Especially in cancer of unknown primary tumour, the discrimination between primary peritoneal tumours and peritoneal metastases is difficult and often requires immunohistochemical identification.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritonitis / pathology. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030433.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Halldorsson A, Dissanaike S, Kaye KS: Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour. J Clin Pathol; 2005 Nov;58(11):1211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung: a clinicopathological description of a case of this very unusual tumour.
  • Alveolar adenomas are extremely rare, and are probably benign lung tumours of unknown histogenesis.
  • A chest x ray and computerised tomography scan demonstrated a solitary left lower lobe lung nodule.
  • Although a positron emission tomography scan seemed to document the benign nature of the lesion, a thoracoscopic wedge resection was performed to alleviate the symptoms and verify the diagnosis.
  • Histologically, the lesion was well demarcated, dominated by large and small cysts with no normal lung parenchyma.
  • [MeSH-major] Adenoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):155-9 [15173924.001]
  • [Cites] Pathologe. 1990 Jan;11(1):48-54 [2179944.001]
  • [Cites] Pathologe. 1996 Mar;17(2):150-3 [8650145.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):34-7 [8689607.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):101-8 [8917711.001]
  • [Cites] Virchows Arch. 1997 Feb;430(2):181-4 [9083522.001]
  • [Cites] Pol J Pathol. 2003;54(2):147-52 [14575424.001]
  • [Cites] Cesk Patol. 1997 May;33(2):49-52 [9340215.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):158-67 [10029443.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):1066-71 [3759064.001]
  • [Cites] Ann Pathol. 1999 Sep;19(4):325-8 [10544770.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Rontgenpraxis. 1997 Feb;50(2):29-30 [9173555.001]
  • (PMID = 16254114.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770767
  •  go-up   go-down


9. Clements D, Asprey SL, McCulloch TA, Morris TA, Watson SA, Johnson SR: Analysis of the oestrogen response in an angiomyolipoma derived xenograft model. Endocr Relat Cancer; 2009 Mar;16(1):59-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipomas are benign mesenchymal tumours of smooth muscle, blood vessels and fat which occur sporadically or associated with tuberous sclerosis and lymphangioleiomyomatosis (LAM), a rare cystic lung disease.
  • To address this question, we created a xenograft tumour system in nude mice using immortalised angiomyolipoma cells.
  • Angiomyolipoma xenografts had active S6K1, p38, p42/44 MAPK and Akt; they grew more rapidly and had greater Akt phosphorylation after oestrogen treatment of tumour-bearing mice.
  • [MeSH-major] Angiomyolipoma / metabolism. Estrogens / pharmacology. Lung Neoplasms / metabolism. MAP Kinase Signaling System / drug effects. MAP Kinase Signaling System / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988705.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens; 0 / Lymphokines; 0 / Multiprotein Complexes; 0 / Platelet-Derived Growth Factor; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 0 / platelet-derived growth factor C; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


10. Katabami M, Okamoto K, Ito K, Kimura K, Kaji H: Bronchogenic glomangiomyoma with local intravenous infiltration. Eur Respir J; 2006 Nov;28(5):1060-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung glomus tumours are quite rare.
  • The current authors present the first reported case of a lung-derived glomangiomyoma, the rarest variant of glomus tumour.
  • After a right lower lobectomy, a diagnosis of glomangiomyoma was made.
  • The tumour had grown endobronchially and its maximal diameter was 5.5 cm.
  • Although cytologically benign, glomus tumour cells had visibly infiltrated neighbouring vessels.
  • [MeSH-major] Carcinoma, Bronchogenic / pathology. Glomus Tumor / pathology. Myoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074921.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Voicu-Măceşeanu A, Nitu M, Olteanu M, Bică D: [Epidemiology of lung cancer]. Pneumologia; 2007 Apr-Jun;56(2):78-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of lung cancer].
  • Lung cancer is nowadays the most spread cancer worldwide, being the main cause of death of all cancers.
  • Lung cancer is the most important and frequent type of lung tumour, representing over 90% of all cases of primary malignant and benign lung tumours.
  • The most deaths of lung cancer occur at 35-75 age group.
  • In the eighties, lung cancer was estimated to be almost 16% of all cancers worldwide and almost 23% of all cancers in Europe.
  • In 1999, lung cancer relative frequency in USA was on top, being followed by colonic cancer and breast cancer relative frequency.
  • In the same year, relative frequency of lung cancer was higher in USA than in Romania both for men (33.97% to 28.4%) and for women (about three times higher in USA than in Romania).
  • According to statistics, lung cancer mortality rate in Romania in 1999 was on the first place in men (comparative with mortality rate of other cancers) and on the third place in women (after breast cancer and uterine collum cancer mortality rate).
  • Lung cancer mortality rate in Romania increased significantly in 1985-2003 period, from 24.9%000 in 1985, to 39.7%000 in 2003.
  • In 2000 year, lung cancer incidence for men in Romania (67.1%000) was lower than in Yugoslavia, Croatia, Bosnia-Herzegovina and Bulgaria but higher than its corresponding value in Macedonia and Albania.
  • Prospective statistic studies estimate that in 2020 year lung cancer incidence for men will be the highest in Greece, Spain and France and the lowest in Great Britain, Ireland, Finland and Sweden.
  • For women, the highest lung cancer incidence is estimated to be in Holland, Denmark and Austria and the lowest in Spain, Ireland and Finland.
  • [MeSH-major] Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019752.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


12. Das SK, Mukherjee RS, Das A, Halder AK, Saha SK: A case of haemoptysis due to endobrnchial fibroma, a rare benign tumour of lung. Lung India; 2008 Jan;25(1):25-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of haemoptysis due to endobrnchial fibroma, a rare benign tumour of lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1969 Dec;8(6):542-60 [4311992.001]
  • [Cites] Dis Mon. 1991 May;37(5):271-318 [2019220.001]
  • [Cites] Eur Radiol. 1998;8(8):1422-4 [9853228.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Apr;30(4):673-8 [1405087.001]
  • [Cites] Am Rev Respir Dis. 1974 Sep;110(3):350-3 [4413229.001]
  • [Cites] Chest. 1984 Jun;85(6):787-91 [6723391.001]
  • (PMID = 20390070.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2851150
  • [Keywords] NOTNLM ; Benign tumours of lung / Endobronchial fibroma / Haemoptysis
  •  go-up   go-down


13. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


14. Alberto VO, Kelleher D, Denholm RB, Nutt M, Carney JA: A calcified lung tumour and microcytic anaemia in a young woman: partial expression of the Carney triad. Surgeon; 2008 Aug;6(4):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A calcified lung tumour and microcytic anaemia in a young woman: partial expression of the Carney triad.
  • Fewer than 100 cases of the disorder have been reported since its description in 1977.
  • The lung chondromas are benign neoplasms and ordinarily not symptomatic.
  • If a diagnosis of the tumour can be established by biopsy, surgical resection may not be necessary.
  • [MeSH-major] Anemia / complications. Calcinosis / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Humans. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697369.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


15. Preuss J, Woenckhaus C, Thierauf A, Strehler M, Madea B: Non-diagnosed pulmonary hyalinizing granuloma (PHG) as a cause of sudden unexpected death. Forensic Sci Int; 2008 Aug 6;179(2-3):e51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hyalinizing granuloma (PHG), a very rare benign tumour of the lungs, was first reported in 1977.
  • However, this drastic measure was avoided by autopsy and a correct interpretation of the solid-elastic and well-circumscribed lung tumour as not characteristic for tuberculosis.
  • Although the final diagnosis of PHG was only achieved after histology, this case strongly illustrates the necessity of a profound morphological training of forensic physicians.
  • [MeSH-major] Death, Sudden / etiology. Granuloma, Respiratory Tract / diagnosis. Lung Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Erythrocyte Count. Female. Forensic Pathology. Humans. Hyalin / metabolism. International Normalized Ratio. Lung / pathology. Lymphoma / diagnosis. Partial Thromboplastin Time. Tuberculosis / diagnosis. Yemen

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621495.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


16. Lazaretti NS, Dallagasperina VW, Villaroel RU, Schlittler LA: [Giant cell tumour of distal femur with pulmonary metastases]. Rev Port Pneumol; 2010 Mar-Apr;16(2):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumour of distal femur with pulmonary metastases].
  • [Transliterated title] Tumor de células gigantes de fémur distal com metástases pulmonares.
  • Gian cell is normally a benign primary skeletal lesion located in the epiphysis of the long bones.
  • It is more frequente in the third and fourth decades of life but can exhibit the behaviour of a malignant tumour with distal metatasis.
  • Up to 10% of patients present distal metatasis, usually in the lung, and it is concomitant to recurrence in the primary site.
  • The treatment of primary tumour is extensive surgical resection.
  • We report a case of a 35-year-old patient with lung metatases 21 months after curettage of giant cell tumour in distal femur.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437009.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


17. Bitterlich N, Muley T, Schneider J: Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation. Anticancer Res; 2010 May;30(5):1661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
  • The diagnosis of non-small cell lung cancer (NSCLC) by using tumour markers needs to be improved and standardised in order to compare marker profiles from different centres.
  • A centre-independent tool based on receiver operating characteristics (ROC) curves instead of cut-off-based approaches for NSCLC diagnosis was established.
  • Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were measured in 326 NSCLC patients and 160 patients with benign lung diseases (Heidelberg, HD) and compared to 158 NSCLC patients and 128 controls from an occupational medicine high-risk cohort (Giessen, GI).
  • The cohorts differed in tumour-stages, marker cut-offs and therefore in sensitivity for NSCLC detection.
  • The diagnosis of NSCLC based on ROC curves eliminate centre-specific differences.
  • Classification methods lead to an improvement in NSCLC diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / biosynthesis. Cohort Studies. Female. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Models, Statistical. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592358.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19
  •  go-up   go-down


18. Pavic M, Debourdeau P, Vacelet V, Rousset H: [Sarcoidosis and sarcoid reactions in cancer]. Rev Med Interne; 2008 Jan;29(1):39-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Place de la pathologie granulomateuse au cours des cancers.
  • Here, we present a literature review about the association of granulomatosis and neoplasia.
  • Patients may rarely present with typical sarcoidosis occurring before, during or after the diagnosis of cancer.
  • Recent studies have documented such a relationship particularly with lymphomas, testicular and lung cancers, melanomas and hepatocarcinomas.
  • Secondly granulomas may be found as a sarcoid reaction in the vicinity of the tumour itself or more frequently in regional lymph nodes.
  • FUTURE PROSPECTS AND PROJECTS: Clinicians need novel non invasive diagnostic methods to differentiate neoplasia from benign sarcoid reactions.

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054124.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 93
  •  go-up   go-down


19. Neuman J, Rosioreanu A, Schuss A, Turi G, Yung E, Trow TK, Williams L, Katz DS: Radiology-pathology conference: sclerosing hemangioma of the lung. Clin Imaging; 2006 Nov-Dec;30(6):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-pathology conference: sclerosing hemangioma of the lung.
  • Sclerosing hemangioma (SH) is a relatively rare, benign neoplasm of the lung.
  • We report the radiology and pathology of a patient with a SH, with emphasis on the computed tomographic and (18)F-fluorodeoxyglucose positron emission tomography findings, and review the literature on this unusual tumor.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung / radiography. Lung / radionuclide imaging. Positron-Emission Tomography / methods. Pulmonary Sclerosing Hemangioma / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101410.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 18
  •  go-up   go-down


20. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev; 2007 Feb 15;21(4):379-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
  • BRaf(CA) mice infected with an Adenovirus expressing Cre recombinase developed benign lung tumors that only rarely progressed to adenocarcinoma.
  • Moreover, BRaf(VE)-induced lung tumors were prevented by pharmacological inhibition of MEK1/2.
  • Consistent with Ink4a/Arf and TP53 tumor suppressor function, BRaf(VE) expression combined with mutation of either locus led to cancer progression.


21. Yang CJ, Cheng YJ, Kang WY, Huang MS, Hwang JJ: A case of dermoid cyst ruptured into the lung. Respirology; 2007 Nov;12(6):931-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of dermoid cyst ruptured into the lung.
  • We present an extremely rare case of a 45-year-old woman who, during a routine health assessment was noted to have a well-defined anterior mediastinal tumour with peripheral ground glass opacity on chest CT.
  • Despite most cystic teratomas being asymptomatic and benign, rupture into the pulmonary parenchyma may induce further damage, for which emergency surgical intervention is always necessary.
  • [MeSH-major] Dermoid Cyst / complications. Lung Diseases / etiology. Mediastinal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986128.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Kalebi AY, Hale MJ, Wong ML, Hoffman T, Murray J: Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome. J Cardiothorac Surg; 2009;4:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update review on the Doege-Potter syndrome.
  • The association of paraneoplastic hypoglycemia [Doege-Potter syndrome] and finger clubbing [Pierre-Marie-Bamberg syndrome] with pleural solitary fibrous tumour is rare.
  • The mean diameter of these tumours manifesting with hypoglycemia is 20 cm, 54% being benign while 42% were malignant.
  • [MeSH-major] Hypoglycemia / surgery. Osteoarthropathy, Secondary Hypertrophic / surgery. Paraneoplastic Syndromes / surgery. Solitary Fibrous Tumor, Pleural / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Glucose / analysis. C-Peptide / analysis. Female. Humans. Insulin / analysis. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1995 Apr;26(4):440-9 [7705824.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):810-3 [7724120.001]
  • [Cites] Magn Reson Imaging. 1997;15(3):377-9 [9201687.001]
  • [Cites] APMIS. 1997 Jun;105(6):469-82 [9236865.001]
  • [Cites] Ann Thorac Surg. 1998 May;65(5):1461-4 [9594894.001]
  • [Cites] Diabetologia. 1998 May;41(5):589-94 [9628278.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18443-51 [9660813.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jan;15(1):84-6 [10077378.001]
  • [Cites] Lung Cancer. 1999 Jan;23(1):53-60 [10100146.001]
  • [Cites] Ann Thorac Surg. 1999 May;67(5):1456-9 [10355431.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):757-8 [10471466.001]
  • [Cites] Mt Sinai J Med. 2004 Oct;71(5):344-6 [15543436.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):944-7 [15569027.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):79-84 [15626921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11047-52 [16040806.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):197-201 [16354315.001]
  • [Cites] Thorac Cardiovasc Surg. 2006 Feb;54(1):65-7 [16485194.001]
  • [Cites] Intern Med. 2006;45(8):525-9 [16702745.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):40-4 [16788942.001]
  • [Cites] J Assoc Physicians India. 2006 May;54:413-5 [16909744.001]
  • [Cites] J Am Coll Surg. 2006 Sep;203(3):398 [16931312.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Sep;132(3):713-4 [16935145.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):478-81 [17180519.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):588-90 [17409923.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 May;31(5):955-7 [17317199.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1600-5 [17299065.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1616 [17483375.001]
  • [Cites] Am Surg. 2007 May;73(5):478-80 [17521003.001]
  • [Cites] Ann Thorac Surg. 2007 Jul;84(1):292-4 [17588442.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Sep;32(3):403-8 [17646108.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5 Suppl):S106-10 [17938018.001]
  • [Cites] Pathol Int. 2007 Dec;57(12):791-3 [17988280.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(6):595-9 [18040628.001]
  • [Cites] Respiration. 2008;75(1):109-12 [17259691.001]
  • [Cites] J BUON. 2008 Jan-Mar;13(1):117-21 [18404798.001]
  • [Cites] Spine (Phila Pa 1976). 2008 May 20;33(12):E397-9 [18496336.001]
  • [Cites] Int J Surg. 2008 Aug;6(4):298-301 [18579460.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1627-42 [18753943.001]
  • [Cites] Endocr J. 2008 Oct;55(5):905-11 [18552458.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jan;119(1):185-7 [10612786.001]
  • [Cites] J Endocrinol. 2000 May;165(2):253-60 [10810289.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2000;108(8):515-8 [11149628.001]
  • [Cites] J Cardiovasc Surg (Torino). 2000 Oct;41(5):781-4 [11149649.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6C):4701-6 [11205204.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):185-9 [11167110.001]
  • [Cites] J Korean Med Sci. 2001 Apr;16(2):220-4 [11306751.001]
  • [Cites] Intern Med. 2001 Apr;40(4):341-4 [11334396.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Clin Orthop Relat Res. 2003 Jun;(411):236-44 [12782880.001]
  • [Cites] Med Oncol. 2003;20(4):403-8 [14716039.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):460-2 [15043457.001]
  • [Cites] J Natl Med Assoc. 2004 May;96(5):659-62, 664 [15160981.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] N Engl J Med. 1982 May 13;306(19):1178-9 [7040961.001]
  • [Cites] Aust N Z J Med. 1982 Feb;12(1):70-2 [7044359.001]
  • [Cites] Arch Intern Med. 1983 Aug;143(8):1608-10 [6870444.001]
  • [Cites] Chest. 1986 Feb;89(2):289-90 [3943390.001]
  • [Cites] N Engl J Med. 1988 Dec 1;319(22):1434-40 [3185662.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] South Med J. 1990 Jun;83(6):690-4 [2162571.001]
  • [Cites] Thorax. 1991 Dec;46(12):932-3 [1792644.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):110-5 [1618998.001]
  • [Cites] J Ky Med Assoc. 1992 Nov;90(11):557-60 [1474302.001]
  • [Cites] Chest. 1994 Sep;106(3):965-7 [8082393.001]
  • (PMID = 19689813.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin
  • [Number-of-references] 78
  • [Other-IDs] NLM/ PMC2739517
  •  go-up   go-down


23. McHugh K: Renal and adrenal tumours in children. Cancer Imaging; 2007;7:41-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of renal and supra-renal masses firstly depends on the age of the child.
  • Neuroblastoma (NBL) may be seen antenatally or in the newborn period; this tumour has a good prognosis unlike NBL seen in older children (particularly NBL in those aged 2-4 years).
  • Benign renal masses predominate in early infancy but beyond the first year of life Wilms' tumour is the most common renal malignancy, until adolescence when renal cell carcinoma has similar or increased frequency as children get older.
  • Adrenal adenomas and carcinomas also occur in childhood; these tumours are indistinguishable on imaging but criteria for the diagnosis of adrenal carcinoma include size larger than 5 cm, a tendency to invade the inferior vena cava and to metastasise.
  • Topics covered include a proposed revision to the staging of NBL, the problems inherent in distinguishing nephrogenic rests from Wilms' tumour and the current recently altered approach regarding small lung nodules in children with Wilms' tumour.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Diagnostic Imaging / methods. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Age of Onset. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / epidemiology. Child. Child, Preschool. Diagnosis, Differential. Ganglioneuroblastoma / diagnosis. Ganglioneuroblastoma / epidemiology. Ganglioneuroblastoma / pathology. Humans. Infant. Infant, Newborn. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Mass Screening. Neoplasm Staging. Neuroblastoma / diagnosis. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / secondary. Neuroblastoma / therapy. Pheochromocytoma / diagnosis. Pheochromocytoma / epidemiology. Positron-Emission Tomography. Tomography, X-Ray Computed. Wilms Tumor / diagnosis. Wilms Tumor / epidemiology. Wilms Tumor / pathology. Wilms Tumor / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60 [16216623.001]
  • [Cites] Urology. 2005 Dec;66(6):1296-300 [16360460.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 May;19(5):749-56 [16789642.001]
  • [Cites] Eur J Radiol. 2001 Feb;37(2):72-8 [11223474.001]
  • [Cites] Eur Radiol. 2001;11(10):2071-81 [11702143.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):18-22 [12426681.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):29-43 [12533638.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):1005-7 [12826894.001]
  • [Cites] Eur J Pediatr. 2003 Sep;162(9):623-8 [12811553.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Pediatr Surg Int. 2004 Jan;20(1):27-32 [14689211.001]
  • [Cites] J Pediatr Surg. 2004 May;39(5):759-63 [15137014.001]
  • [Cites] J Nucl Med. 2004 Jul;45(7):1172-88 [15235064.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1575-83 [15378495.001]
  • [Cites] Cancer. 1987 Jun 1;59(11):1853-9 [3567848.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1171-82 [9060561.001]
  • [Cites] Acta Radiol. 1999 Sep;40(5):534-42 [10485244.001]
  • (PMID = 17339140.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  • [Other-IDs] NLM/ PMC1828369
  •  go-up   go-down


24. Sak SD, Koseoglu RD, Demirag F, Akbulut H, Gungor A: Alveolar adenoma of the lung. Immunohistochemical and flow cytometric characteristics of two new cases and a review of the literature. APMIS; 2007 Dec;115(12):1443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar adenoma of the lung. Immunohistochemical and flow cytometric characteristics of two new cases and a review of the literature.
  • Alveolar adenoma is a rare and benign tumour of the lung that usually presents in asymptomatic patients as a coin lesion on chest radiography.
  • Alveolar adenoma has a characteristic multicystic histology and often resembles the normal lung parenchyma.
  • Immunohistochemical analysis may aid in the characterization of alveolar adenoma and discriminate this condition from other types of benign lesions of the lung.
  • An indolent clinical progression and absence of recurrence and metastasis after complete resection are the most important characteristics indicative of the benign nature of alveolar adenoma.
  • In this article we describe the immunohistochemical and flow cytometric features of this neoplasm in two male patients.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Proliferation. Flow Cytometry. Humans. Immunohistochemistry. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184418.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • MUC4, a large transmembrane mucin, has recently emerged as a novel marker for diagnosis, prognosis and therapy in several malignancies.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


27. Kurkcuoglu IC, Demircan S, Kurul IC, Demirag F: Endobronchial lipomatous hamartoma. Asian Cardiovasc Thorac Ann; 2005 Dec;13(4):372-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hamartomas are the most common benign neoplasm of the lung, occurring in the parenchyma or sometimes within the bronchi.
  • Reported is a case of a 64-year-old male patient with an endobronchial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304229.001).
  • [ISSN] 0218-4923
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Wallowy P, Diener J, Grünwald F, Kovács AF: 18F-FDG PET for detecting metastases and synchronous primary malignancies in patients with oral and oropharyngeal cancer. Nuklearmedizin; 2009;48(5):192-9; quiz N42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 74 of 80 evaluable cases, PET showed the primary tumour (92.5%).
  • Main sites were the lung, the upper aerodigestive tract, and the gastrointestinal system.
  • In the other 58 cases (69%), where the suspect lesions were confirmed as benign, mean SUV was 2.65 (range 0.7-6.5) (difference statistically significant).
  • [MeSH-major] Fluorodeoxyglucose F18. Mouth Neoplasms / pathology. Mouth Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Staging. Palatal Neoplasms / pathology. Palatal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Retrospective Studies. Tongue Neoplasms / pathology. Tongue Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623408.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Zhao Z, Huang Q, Zhao T, Zhao J: [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):176-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer].
  • BACKGROUND: The promyelocytic leukaemia (PML) protein has been implicated in control of key tumor-suppressive pathways.
  • However, its role in pathogenesis of lung cancer is still unclear.
  • The objective of this study is to assess expression and clinical significance of PML, P53 and P16INK4A in lung cancer, as well as the relation of these factors.
  • METHODS: The tissue microarrays were created with samples from lung cancers (n=148), pulmonary benign lung tumors (n=5) and normal lung tissues (n=7), and protein expression was analyzed by immunohistochemical staining.
  • RESULTS: There was at least triplicate 0.6-mm cores per sample, 4 cases of lung cancer were excluded for lacking of enough tissue.
  • P53 expression was found in 33.3% lung cancer, and absent in benign tumors and normal tissues of the lung (P=0.038).
  • P16INK4A expression was abolished in normal lung tissue, however, increased in lung cancer (28.5%), and especially in lung cancer with non- or poor differentiation (36.5%) and in SCLC (69.6%).
  • There was inverse correlation between PML expression in the nuclei and P16INK4A expression, positive correlation between P53 and P16INK4A expressions in lung cancers.
  • CONCLUSIONS: As an important suppressor of tumor, PML is related with P53 mutation in squamous cell carcinoma.
  • Increased P16INK4A protein in lung cancer may be the results of gene mutation, and be related with mutant P53 protein.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118641.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Jarkiewicz-Kochman E, Gołebiowski M, Swiatkowski J, Pacholec E, Rajewski R: Tumours of the metatarsus. Ortop Traumatol Rehabil; 2007 May-Jun;9(3):319-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Single cases of the following tumours have been discussed: giant cell tumour, metastases (lung, prostate gland), chondroblastoma, aneurysmal bone cyst, Ewing's sarcoma, clear cell carcinoma, osteosarcoma, intraosseous ganglion, chondromyxoid fibroma and granuloma.
  • The aim of the present study was to carry out a systematic examination of metatarsal tumours with regard to methods of diagnosis (location) and morphology.
  • RESULTS: Most of the metatarsal tumours were benign.
  • 4. The frequently unequivocal presentation of metatarsal tumours requires a multidisciplinary diagnosis involving a clinician, a radiologist and a histopathologist.
  • [MeSH-major] Bone Neoplasms / diagnosis. Metatarsal Bones / radiography
  • [MeSH-minor] Adult. Bone Cysts, Aneurysmal / diagnosis. Diagnosis, Differential. Female. Giant Cell Tumor of Bone / diagnosis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Osteochondroma / diagnosis. Osteoma / diagnosis. Sarcoma, Synovial / diagnosis. Soft Tissue Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721430.001).
  • [ISSN] 1509-3492
  • [Journal-full-title] Ortopedia, traumatologia, rehabilitacja
  • [ISO-abbreviation] Ortop Traumatol Rehabil
  • [Language] eng; pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


31. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


32. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE: Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology; 2010 Apr;42(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
  • AIMS: Cytology fails to detect neoplastic cells in 40-50% of cases of malignant pleural effusion, a condition that frequently accompanies lung adenocarcinoma.
  • Published reports of diagnostic sensitivity of various tumour markers are inconsistent, and optimal cut-off points have not been determined.
  • This study aimed to evaluate the ability of three markers to discriminate lung adenocarcinoma-associated malignant pleural effusion (LAC-MPE) from benign effusion.
  • METHODS: Pleural effusion samples were collected from 41 patients with LAC-MPE, and from 93 with various benign conditions.
  • RESULTS: Her-2/neu, Cyfra 21-1, and CEA vary in their diagnostic accuracy to differentiate LAC-MPE from benign pleural effusion: 79.85%, 88.81%, and 94.03%, respectively.
  • The results of the present study may help clinicians decide whether to obtain a cytological/histological specimen by invasive means to investigate a possible diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / analysis. Carcinoembryonic Antigen / analysis. Keratin-19 / analysis. Lung Neoplasms / diagnosis. Pleural Effusion / metabolism. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350214.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


33. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S: Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice. Carcinogenesis; 2009 Aug;30(8):1398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice.
  • We also showed that the antioxidant N-acetylcysteine (NAC) prevents the extensive nucleotide and gene expression alterations that occur 'physiologically' at birth in mouse lung.
  • The present study was designed to evaluate whether administration of NAC during pregnancy may affect the yield of tumors in mice exposed to MCS, starting after birth and continuing for 120 days.
  • In contrast, as much as the 61.1% (33/54) of MCS-exposed mice born from untreated dams had lung tumors, including both benign tumors and bronchoalveolar carcinomas.
  • Treatment with NAC during pregnancy strikingly inhibited the formation of benign lung tumors and totally prevented occurrence of carcinomas.
  • These findings demonstrate for the first time that treatment during pregnancy with an antioxidant chemopreventive agent can affect the induction of tumors consequent to exposure to a carcinogen after birth.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2003 Nov;544(2-3):441-9 [14644347.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1127-9 [12709406.001]
  • [Cites] Toxicol Lett. 2004 Mar 14;148(1-2):1-9 [15019083.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):85-90 [15313581.001]
  • [Cites] Chem Biol Interact. 1988;68(3-4):259-71 [3214887.001]
  • [Cites] Ann Emerg Med. 1991 Oct;20(10):1069-72 [1928876.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1545-8 [8353839.001]
  • [Cites] Life Sci. 1994;54(26):2055-9 [8208062.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):839-45 [7645968.001]
  • [Cites] FASEB J. 2005 Mar;19(3):470-2 [15634872.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):3-18 [15765916.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1488-92 [15930027.001]
  • [Cites] South Med J. 2005 Nov;98(11):1118-22 [16351032.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):521-9 [16865267.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2116-23 [16704990.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1101-11 [16861382.001]
  • [Cites] DNA Repair (Amst). 2006 Nov 8;5(11):1392-7 [16916625.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1001-6 [17283132.001]
  • [Cites] Hum Exp Toxicol. 2007 Feb;26(2):99-103 [17370867.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2236-43 [17522065.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):137-46 [18155953.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1581-6 [18635525.001]
  • [Cites] Mutat Res. 2008 Sep 26;644(1-2):38-42 [18640134.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2497-502 [18770867.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):315-20 [19073876.001]
  • [Cites] Oncol Rep. 2009 Sep;22(3):469-74 [19639190.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):999-1013 [11408342.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1166-76 [14647414.001]
  • (PMID = 19458036.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Free Radical Scavengers; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2718074
  •  go-up   go-down


34. Shapeero LG, De Visschere PJ, Verstraete KL, Poffyn B, Forsyth R, Sys G, Uyttendaele D: Post-treatment complications of soft tissue tumours. Eur J Radiol; 2009 Feb;69(2):209-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Fifty-one patients (29 males and 22 females, ages 14-80 years) with 34 malignant and 17 benign soft tissue tumours were evaluated for local and distant complications after resection or amputation only (26 patients) or after the addition of radiotherapy (25 patients: 17 patients had external beam therapy, 7 patients had external beam therapy and brachytherapy, and one patient had extracorporeal irradiation and reimplantation).
  • Duration of follow-up averaged 3.75 years for malignant tumours and 2.79 years for benign tumours.
  • Metastases from soft tissue sarcomas, most commonly to lung (nine patients) and to bone and muscle (five patients), showed no specific relationship to type of therapy.
  • In nerve entrapment, DCE-MRI demonstrated the rapidly enhancing recurrent tumour or non-enhancing fibrosis surrounding the slowly enhancing nerve.
  • Diligent follow-up of patients with soft tissue tumours with recognition of these complications and their differentiation from recurrent or residual tumour can help guide clinical care and may negate the need for surgery when benign disease is defined.
  • [MeSH-major] Postoperative Complications / diagnosis. Postoperative Complications / etiology. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects. Soft Tissue Neoplasms / complications. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101106.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


35. Lizarbe MO, Olascoaga JH, García ER, Castiella TM, Sagaseta de Ilúrdoz Uranga María M, Garicano JM: [Paediatric myofibroblastic tumours. A presentation of three cases]. An Pediatr (Barc); 2009 Oct;71(4):331-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumor miofibroblástico en la edad pediátrica. A propósito de 3 casos.
  • This a rare benign disease, that can develop into malignant forms.
  • The symptoms that indicated the location of the tumour were, haematemesis in the first case, and respiratory disease in the third.
  • All cases had increased CRP, ESR, thrombocytosis and high levels of gamma globulins Surgery is curative if total resection is possible, and the diagnosis is made by histopathology.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Intestinal Diseases / diagnosis. Lung Diseases / diagnosis. Stomach Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2010 Oct;73(4):221-2 [20705527.001]
  • (PMID = 19647502.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Chien NC, Lin CW, Tzeng JE: Sclerosing haemangioma with lymph node metastasis. Respirology; 2009 May;14(4):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing haemangioma (SH) of the lung is an intrapulmonary tumour composed of polygonal and cuboidal cells arranged in a heterogeneous pattern.
  • SH is generally regarded as benign or very low-grade; only rarely have cases of lymph node metastasis been reported.
  • We report a case of SH with metastasis to the regional lymph nodes in an 18-year-old male, whose left lung tumour was identified incidentally on routine CXR.
  • The tumour consisted of proliferative cuboidal and polygonal cells arranged in a papillary pattern within the sclerotic stroma.
  • [MeSH-major] Histiocytoma, Benign Fibrous / secondary. Histiocytoma, Benign Fibrous / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402838.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


37. Lamp O, Honscha KU, Jakob J, Lamp J, Schweizer S, Reischauer A, Gottschalk J, Hahn A, Ebert M, Rothemund S, Blaschzik S, Einspanier A: Investigation of the local expression of the relaxin system in canine mammary tumours. Reprod Domest Anim; 2009 Jul;44 Suppl 2:224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasiveness and angiogenesis, which are important processes of tumour growth and spreading, require connective tissue remodelling.
  • Comparison of hormone concentrations in 93 bitches in terms of benign or malignant nature of the CMT, lung metastases, recidivation and 12-month survival discovered no significances.
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Dogs. Female. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Receptors, Peptide / genetics. Receptors, Peptide / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19754574.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Peptide; 9002-69-1 / Relaxin
  •  go-up   go-down


38. Płachcińska A, Mikołajczak R, Kozak J, Rzeszutek K, Kuśmierek J: Differential diagnosis of solitary pulmonary nodules based on 99mTc-EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment. Eur J Nucl Med Mol Imaging; 2006 Sep;33(9):1041-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of solitary pulmonary nodules based on 99mTc-EDDA/HYNIC-TOC scintigraphy: the effect of tumour size on the optimal method of image assessment.
  • PURPOSE: The aim of the study was to determine an optimal method for the evaluation of scintigrams obtained with (99m)Tc-EDDA/HYNIC-TOC for the purpose of differential diagnosis of solitary pulmonary nodules (SPNs) and to assess the diagnostic value of the method.
  • Patients underwent (99m)Tc-EDDA/HYNIC-TOC scintigraphy for the purpose of differential diagnosis of SPNs (size between 1 and 4 cm).
  • RESULTS: Positive scintigraphic results were found in 37 out of 40 (93%) patients with malignant SPNs including 34 out of 35 (97%) patients with primary lung carcinoma.
  • Among 45 benign tumours, negative results were obtained in 31 cases (69%) and positive results in 14.
  • Uptake of the tracer in those nodules was therefore assessed semi-quantitatively (using the tumour-to-background ratio), in expectation of an improvement in the low specificity of the visual method.
  • [MeSH-major] Lung Neoplasms / diagnostic imaging. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Positron-Emission Tomography / statistics & numerical data. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Feb;125(2):494-501 [14769730.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):84-91 [11965603.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Feb;21(1):61-7 [16480332.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):681-8 [8314345.001]
  • [Cites] Nucl Med Rev Cent East Eur. 2004;7(2):143-50 [15968601.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10 ):1441-56 [11083532.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):104-10 [1355582.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1005-10 [15029463.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10 ):3837-44 [11051227.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):208-21 [15129703.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1850-9 [9581824.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2535-42 [12815140.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Dec;20(6):1101-5 [11717011.001]
  • [Cites] J Biol Chem. 1989 Jan 15;264(2):949-52 [2562957.001]
  • [Cites] Eur J Nucl Med. 2000 Mar;27(3):273-82 [10774879.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2113-25 [9626211.001]
  • [Cites] Chest. 2000 May;117(5):1232-8 [10807805.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):261-70 [15186607.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):823-30 [16570185.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):78 [11965601.001]
  • [Cites] Nucl Med Rev Cent East Eur. 2006;9(1):24-9 [16791800.001]
  • [Cites] Postgrad Med. 2003 Aug;114(2):29-35; quiz 16 [12926175.001]
  • (PMID = 16715455.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium 99m EDDA-HYNIC-Tyr(3)-octreotide
  •  go-up   go-down


39. Haruki T, Nakamura H, Taniguchi Y, Miwa K, Adachi Y, Fujioka S: Pulmonary mucinous cystadenoma: a rare benign tumor of the lung. Gen Thorac Cardiovasc Surg; 2010 Jun;58(6):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary mucinous cystadenoma: a rare benign tumor of the lung.
  • This tumor is histologically characterized by a benign proliferation of mucin-producing epithelial cells and bulky mucin inside the tumor.
  • We present the case of a 71-year-old woman with increasing mass shadow on chest radiography who underwent tumor resection by video-assisted thoracic surgery.
  • The tumor was diagnosed histologically as PMCA.
  • [MeSH-major] Cystadenoma, Mucinous. Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1053-6 [1699507.001]
  • [Cites] Pancreas. 2008 Mar;36(2):168-72 [18376308.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Jul;28(1):176-7 [15939602.001]
  • (PMID = 20549459.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. De Wever W, Stroobants S, Coolen J, Verschakelen JA: Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J; 2009 Jan;33(1):201-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration.
  • Lung cancer is a common disease and is a leading cause of death in many countries.
  • The management of lung cancer is directed by an optimal staging of the tumour.
  • This improvement can result in the detection of lesions initially not seen on CT or PET, a more precise location of lesions, a better characterisation of the lesion as benign or malignant and a better differentiation between tumour and surrounding structures.
  • Initial studies demonstrate better results for PET/CT in the staging of lung cancer in comparison with PET alone, CT alone or visual correlation of PET and CT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Staging. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118231.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 65
  •  go-up   go-down


41. Nakamura H, Adachi Y, Arai T, Miwa K, Haruki T, Fujioka S, Taniguchi Y: A small alveolar adenoma resected by thoracoscopic surgery. Ann Thorac Surg; 2009 Mar;87(3):956-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar adenoma (AA) is a rare lung benign tumor originated from type II pneumocytes.
  • It presents as a well-defined nodule in clinical images, but is difficult to differentiate from early-stage lung cancer.
  • We treated a 58-year-old woman with a small-sized AA measuring 8 x 6 mm in the upper lobe of the left lung by performing a thoracoscopic resection.
  • There have been no reported cases of recurrence after a resection of AA, but a subsequent increase in such cases is expected, and we believe that it is necessary to understand the characteristics of this typical benign lung tumor.
  • [MeSH-major] Adenoma / surgery. Lung Neoplasms / surgery. Thoracoscopy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231437.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Breen DP, Dubus JC, Chetaille B, Payan MJ, Dutau H: A rare cause of an endobronchial tumour in children: the role of interventional bronchoscopy in the diagnosis and treatment of tumours while preserving anatomy and lung function. Respiration; 2008;76(4):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of an endobronchial tumour in children: the role of interventional bronchoscopy in the diagnosis and treatment of tumours while preserving anatomy and lung function.
  • Coring of the mass both allowed histological diagnosis (inflammatory myofibroblastic tumour) and definitive treatment with no recurrence after 3 years of follow-up.
  • This case report emphasizes the major role of interventional bronchoscopy in the management of tumoural obstruction in children in whom benign conditions are frequent.
  • Interventional bronchoscopy, which is minimally invasive when compared to surgery, in the vast majority of cases allows a precise diagnosis as it provides large samples of tissue removed during coring; in some cases it can be curative by itself and preserves lung parenchyma and function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17429193.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


43. Horváth T, Spelda S, Kocáková I, Bartonková H, Cíhalová M, Moulis M, Garajová B, Strazevská E, Vomela J: [Pulmonary segmentectomy for tumour]. Rozhl Chir; 2009 May;88(5):238-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary segmentectomy for tumour].
  • BACKGROUND: An analysis of outcome data of pulmonary segmentectomy focused on local efficacy in primary non small cell lung cancer and true or seeming lung metastasis.
  • PATIENTS AND METHODS: Miscellaneous series of twenty patients treated with classical open procedure involving individuals with primary or metachronous non small cell lung cancer, solitary pulmonary metastasis of extrapulmonary cancer and/or benign pulmonary lesions, lung metastasis mimicing.
  • Third part of the group collects benign pulmonary lesions: chondrohamartoma, pneumonitis and pulmonary infarct.
  • One R1 disease was discovered in a patient with primary lung adenocarcinoma.
  • CONCLUSION: Lung segmentectomy seems to accomplish local control of early stage non small cell lung cancer and pulmonary metastasis of extrapulmonary cancer in selected patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642341.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


44. Rai SP, Patil AP, Saxena P, Kaur A: Laser resection of endobronchial hamartoma via fiberoptic bronchoscopy. Lung India; 2010 Jul;27(3):170-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial hamartoma is a rare benign tumor of lung that may present with symptoms of airway obstruction with wheezing, stridor, recurrent pneumonia or atelectasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931040.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946723
  • [Keywords] NOTNLM ; Diode laser / endobronchial hamartoma / fiberoptic bronchoscope / laser resection
  •  go-up   go-down


45. Pollefliet C, Peters K, Janssens A, Luijks A, Van Bouwel E, Van Marck E, Germonpre P: Endobronchial lipomas: rare benign lung tumors, two case reports. J Thorac Oncol; 2009 May;4(5):658-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial lipomas: rare benign lung tumors, two case reports.
  • Endobronchial lipoma is a rare benign lung tumor.
  • We discuss the epidemiology, difficulties in establishing the diagnosis, and the management of this rare condition.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lipoma / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395910.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hürtgen M, Friedel G, Witte B, Toomes H, Fritz P: Systematic Video-Assisted Mediastinoscopic Lymphadenectomy (VAMLA). Thorac Surg Sci; 2005;2:Doc02
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate mediastinal lymph node dissection during thoracotomy is mandatory for staging and for adjuvant therapy in lung cancer.
  • Pre-therapeutic staging for neoadjuvant therapy or for video assisted thoracoscopic resection of lung cancer is achieved usually by CT-scan and mediastinoscopy.
  • In patients receiving tumour resection subsequently to VAMLA, radicality of the previous mediastinoscopic dissection was controlled during thoracotomy.37 patients underwent video-assisted mediastinoscopy from June 1999 to April 2000.
  • Mean duration of anaesthesia was 84.6 (SD 35.8) minutes.In 7 patients radical lymphadenectomy was not intended because of bulky nodal disease or benign disease.
  • The remaining 30 patients underwent complete systematic nodal dissection as VAMLA.18 patients received tumour resection subsequently (12 right- and 6 left-sided thoracotomies).
  • None of these nodes was positive for tumour.Average weight of the tissue that was harvested by VAMLA was 10.1 g (2.2-23.7, SD 6.3).
  • This is comparable to our historical data from open lymphadenectomy.One palsy of the recurrent nerve in a patient with extensive preparation of the nerve and resection of 11 left-sided enlarged nodes was the only severe complication in this series.VAMLA seems to accomplish mediastinal nodal dissection comparable to open lymphadenectomy and supports video assisted surgery for lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1135-40 [10838529.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Nov;12(5):706-12 [9458140.001]
  • [Cites] Thorac Cardiovasc Surg. 1999 Feb;47(1):42-7 [10218620.001]
  • [Cites] Chest. 1975 Mar;67(3):365-6 [1112136.001]
  • [Cites] Thoraxchir Vask Chir. 1965 Dec;13(6):401-7 [5222569.001]
  • [Cites] Chest. 1997 Dec;112(6):1480-6 [9404742.001]
  • [Cites] Eur Respir J. 1997 Nov;10(11):2529-34 [9426090.001]
  • [Cites] Schweiz Med Wochenschr. 1998 Jun 6;128(23):895-9 [9658517.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Feb;21(2):348-51 [11825753.001]
  • [Cites] Chirurg. 1990 Apr;61(4):308-11 [2347266.001]
  • [Cites] J Laryngol Otol. 1989 Mar;103(3):312-5 [2703776.001]
  • [Cites] Surgery. 1987 Oct;102(4):652-9 [2821640.001]
  • [Cites] J Thorac Cardiovasc Surg. 1987 Nov;94(5):673-8 [3669695.001]
  • [Cites] Dtsch Med Wochenschr. 1967 Dec 22;92(51):2358-61 [6073576.001]
  • [Cites] Eur J Cardiothorac Surg. 1994;8(1):37-42 [8136168.001]
  • [Cites] Ann Thorac Surg. 1993 Apr;55(4):961-6 [8385446.001]
  • [Cites] Eur Respir J. 1996 Dec;9(12):2560-4 [8980969.001]
  • [Cites] Radiology. 1997 Feb;202(2):441-6 [9015071.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Aug;12(2):224-7 [9288511.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Apr;10(2):71-5 [10789576.001]
  • [Cites] Eur Respir J. 1997 Jul;10(7):1547-51 [9230245.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Jul;12(1):92-7 [9262087.001]
  • (PMID = 21289921.001).
  • [ISSN] 1862-4006
  • [Journal-full-title] Thoracic surgical science
  • [ISO-abbreviation] Thorac Surg Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3011310
  • [Keywords] NOTNLM ; carcinoma, non-small-cell lung / lung neoplasm / mediastinoscopy / neoplasm staging / video-assisted surgery
  •  go-up   go-down


47. Daglar G, Yuksek YN, Gozalan U, Tutuncu T, Kama NA: The significance of pulmonary nodule in breast cancer patients. Bratisl Lek Listy; 2010;111(5):280-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Stage, tumour size, treatment, histology, lymph node involvement, adjuvant therapy, were similar in both groups.
  • CONCLUSIONS: For the nodules that show benign properties at tomography, there is no need to do further investigation and no need to change treatment plan in breast cancer patients (Tab. 2, Fig.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Solitary Pulmonary Nodule / complications. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568418.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


48. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


49. Li W, Ni Y, Tu Z, Wu S, Wu Z, Zheng S: Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg; 2009 Sep;36(3):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
  • OBJECTIVE: To detect telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer (NSCLC) and to evaluate its clinical value.
  • METHODS: From July 2005 to May 2007, 167 pleural lavage fluid specimens were obtained from 135 patients with NSCLC and 32 patients with benign lung tumour during operation.
  • Telomerase activity was negative in all 32 patients with benign lung tumour.
  • There was a significant relationship between telomerase activity and pleural extension, T level, N level as well as the clinical TNM (tumour, node, metastasis) stage of lung cancer.
  • CONCLUSION: Telomerase activity is a useful adjunct for cytological method in the diagnosis of pleural micro-metastasis and was related to prognosis in a patient with NSCLC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Pleural Cavity / enzymology. Pleural Neoplasms / secondary. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Clinical Enzyme Tests / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502078.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


50. Duysinx BC, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, Louis R: 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun; 2006 Dec;27(12):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study evaluates the accuracy of [F]fluorodeoxyglucose positron emission tomography (F-FDG PET) imaging with semi-quantitative analysis for differentiating benign from malignant pleural exudates and for guiding the search for the primary tumour of pleural metastases.
  • Thoracoscopy was systematically performed to reveal pathological diagnosis.
  • RESULTS: All SUVs were significantly higher in all malignant pleural diseases (n = 51) than in benign (n = 28) (P < 0.001).
  • Moreover SUVs were greater in the pleural metastases from pulmonary primaries (n = 25) and in mesotheliomas (n = 8) than in extrathoracic primaries (n = 18) (P < 0.01) with no significant difference between lung cancers and mesotheliomas.
  • Receiver operating curve (ROC) analysis between benign and malignant lesions showed areas under the curves that ranged from 0.803 (SUVbsa g) to 0.863 (SUVbw).
  • CONCLUSION: Semi-quantitative analysis of 18F-FDG PET imaging helps to differentiate malignant from benign pleural exudates and to distinguish between thoracic or extrathoracic primaries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088683.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


51. Halley A, Hugentobler A, Icard P, Porret E, Sobrio F, Lerochais JP, Bouvard G, Zalcman G, Agostini D: Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging; 2005 Sep;32(9):1026-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules.
  • PURPOSE: The purpose of the study was to compare ( 18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and ( 99m)Tc-depreotide single-photon emission computed tomography (SPECT) in the diagnosis of malignancy of solitary pulmonary nodules (SPNs).
  • RESULTS: Histological findings revealed 18 malignant nodules and seven benign lesions.
  • Stability over a 2-year period indicated a benign process in the remaining three cases.
  • A carcinoid tumour not visualised on FDG PET was identified by depreotide SPECT.
  • Seven of the ten benign lesions did not reveal tracer uptake on either depreotide SPECT or FDG PET.
  • CONCLUSION: This study showed( 18)F-FDG PET to be more sensitive than ( 99m)Tc-depreotide SPECT in the diagnosis of malignancy of SPNs.
  • [MeSH-minor] Adult. Aged. Female. France. Humans. Lung Neoplasms / diagnostic imaging. Male. Middle Aged. Pilot Projects. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Feb;125(2):494-501 [14769730.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):556-65 [10210213.001]
  • [Cites] Bull Cancer. 2003 Feb;90 Spec No:S1-109 [12744225.001]
  • [Cites] J Nucl Med. 1990 Dec;31(12 ):1927-32 [2266388.001]
  • [Cites] J Med Chem. 1996 Mar 29;39(7):1361-71 [8691466.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1369-73 [9574618.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):1016-22 [8683294.001]
  • [Cites] Bull Cancer. 2003 Feb;90 Spec No:S23-41 [12739334.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1850-9 [9581824.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Dec;29(12 ):1639-47 [12458399.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1771-6 [7965154.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] Lung Cancer. 1993 Dec;10(3-4):151-72 [7915618.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Chest. 1999 Jan;115(1):224-32 [9925088.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2002 Jul;14 (3):261-7 [12232867.001]
  • [Cites] Eur J Clin Invest. 1997 Aug;27(8):645-7 [9279526.001]
  • [Cites] Semin Nucl Med. 2002 Oct;32(4):293-321 [12524653.001]
  • [Cites] Life Sci. 1994;55(23):1797-806 [7968260.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2535-42 [12815140.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] Ann Nucl Med. 2002 May;16(3):213-9 [12126047.001]
  • [Cites] Curr Pharm Des. 2002;8(20):1827-36 [12171534.001]
  • [Cites] Semin Nucl Med. 2002 Oct;32(4):276-92 [12524652.001]
  • [Cites] J Nucl Med. 2002 Jul;43(7):876-81 [12097456.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):89S-96S [12527568.001]
  • [Cites] Chest. 2000 May;117(5):1232-8 [10807805.001]
  • [Cites] AJR Am J Roentgenol. 1998 Apr;170(4):935-9 [9530038.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):214-9 [14960638.001]
  • (PMID = 15877227.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 51110-01-1 / Somatostatin; 9M48M2SF02 / technetium Tc 99m depreotide
  •  go-up   go-down


52. Oshikiri T, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Kaji N, Kondo S: Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. Cancer Lett; 2006 Jun 8;237(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors.
  • We examined a patient with resectable gallbladder cancer with associated lung metastasis.
  • A 64-year-old female patient, diagnosed with gallbladder cancer and a solitary benign lung tumor by imaging, was subjected to extensive cholecystectomy and extrahepatic bile duct resection.
  • After one year, a follow-up CT indicated enlargement of the lung tumor; video-assisted right middle lobectomy was then performed.
  • The lung tumor was diagnosed as a metastasis derived from the gallbladder cancer by pathology and immunohistochemistry.
  • Expression of RCAS1, an independent unfavorable prognostic indicator in gallbladder cancer, was observed in both the gallbladder and lung tumors.
  • However, infiltration of CD8+T cells was only seen in the lung metastatic tumor.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, Neoplasm / metabolism. CD8-Positive T-Lymphocytes / pathology. Gallbladder Neoplasms / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039043.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human
  •  go-up   go-down


53. Abdennadher M, Kolsi M, Khabir A, Abdelmalek M, Boudaoura T, Frikha I: [Pulmonary myofibroblastoma: the role of primary surgery]. Rev Mal Respir; 2005 Dec;22(6 Pt 1):1043-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumeur myofibroblastique pulmonaire: intérêt de la chirurgie première.
  • INTRODUCTION: Myofibroblastic tumours or pulmonary pseudotumours are rare and, though benign, they may become invasive and recur after excision.
  • CASE REPORT: We report the case of a child aged 14, presenting with mild haemoptysis, who had a solitary nodule at the base of the left lung.
  • CT scanning suggested a hypervascular tumour.
  • Histological examination revealed a myofibroblastic tumour.
  • CONCLUSION: Recourse to primary surgery is essential to confirm the diagnosis of a myofibroblastic pulmonary tumour.
  • [MeSH-major] Lung Neoplasms. Neoplasms, Muscle Tissue
  • [MeSH-minor] Adolescent. Bronchoscopy. Follow-Up Studies. Humans. Lung / pathology. Male. Radiography, Thoracic. Thoracotomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598865.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Yang A, Xue J, Li X, Yu Y, Deng H, Hu G, Meng X, Li J: Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun; 2007 Sep;28(9):696-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer.
  • BACKGROUND: 99mTc-methoxyisobutylisonitrile (99mTc-MIBI) has been used as a tumour positive scintigraphic agent for diagnostic purposes.
  • However, the pharmaceutical kinetics and accumulation patterns of 99mTc-MIBI in tumour tissues (both in vitro and in vivo) remained poorly understood.
  • Using human embryonic lung fibroblasts (HLFs) as a control, we investigated the kinetics of 99mTc-MIBI accumulation in four human cancer cell lines.
  • RESULTS: We found that, among the tested groups, the uptake rate (UR) of 99mTc-MIBI in normal lung fibroblast cells was the lowest at 90 min after injection, while the UR of four groups of carcinoma cells increased significantly.
  • We also used a semi-quantitative method to analyse 99mTc-MIBI imaging results from 93 clinical cases of pathologically or cytologically confirmed lung cancer lesions.
  • We found that the UR value of a lung benign lesion group was significantly lower than that of a malignant lesion group.
  • We conclude that the sensitivity, specificity and accuracy of 99mTc-MIBI imaging for the lung occupied cancer lesions were 89.83%, 79.41% and 86.02%, respectively.
  • CONCLUSION: These observations demonstrate a close relationship between the state of 99mTc-MIBI accumulation and the metabolic level of tumour cells and the P-gp expression.
  • Our data suggest that 99mTcc-MIBI semi-quantitative imaging is useful for the qualitative diagnosis of lung-occupied cancer lesions and may be a potential predictor of the P-gp expression in the clinic.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. P-Glycoprotein / biosynthesis. Radiopharmaceuticals / pharmacology. Technetium Tc 99m Sestamibi / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Fibroblasts / metabolism. Humans. Lung / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nucl Med Commun. 2008 Mar;29(3):303 [18349803.001]
  • (PMID = 17667748.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


55. Burnei G, Georgescu I, Vlad C, Gavrliu S, Drăghici IM, Dan D, Burnei C: Symptomatology and exploration methods of pulmonary tumours in children. Rom J Intern Med; 2007;45(1):97-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis within the first 15 weeks of pregnancy will allow the parents to make a decision regarding the future evolution.
  • At present, the symptomatology allows detecting the tumour at approximately 9-12 months since its appearance, and Rx/anatomopathological exploration can confirm or deny the diagnosis, offering information on its primitive or metastasised, benign or malignant, operable or non-operable character.
  • [MeSH-major] Lung Neoplasms / complications. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Cohort Studies. Diagnostic Imaging. Female. Humans. Infant. Male. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966450.001).
  • [ISSN] 1220-4749
  • [Journal-full-title] Romanian journal of internal medicine = Revue roumaine de médecine interne
  • [ISO-abbreviation] Rom J Intern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


56. Onuma K, Sato Y, Ogawara S, Shirasawa N, Kobayashi M, Yoshitake J, Yoshimura T, Iigo M, Fujii J, Okada F: Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol; 2009 Nov;175(5):2171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.
  • We found that mice that were cotransplanted subcutaneously with QR-32 cells and nano-sized TiO(2), either uncoated (TiO(2)-1, hydrophilic) or coated with stearic acid (TiO(2)-2, hydrophobic), did not form tumors.
  • However, QR-32 cells became tumorigenic after injection into sites previously implanted with TiO(2)-1, but not TiO(2)-2, and these developing tumors acquired metastatic phenotypes.
  • These results indicate that nano-sized TiO(2) has the potential to convert benign tumor cells into malignant ones through the generation of ROS in the target cells.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Fibrosarcoma. Nanoparticles / chemistry. Neoplasm Invasiveness. Titanium / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytokines / genetics. Cytokines / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Dinoprostone / metabolism. Female. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Inbred C57BL. Particle Size. Reactive Oxygen Species / metabolism. Thymosin / genetics. Thymosin / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Med. 1988 Dec;30(12):937-42 [3230444.001]
  • [Cites] J Toxicol Environ Health. 1990;29(4):417-29 [2325155.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(6):358-64 [2386981.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5512-20 [8955201.001]
  • [Cites] J Biochem. 1997 Aug;122(2):459-66 [9378727.001]
  • [Cites] Br Med Bull. 1997;53(3):662-8 [9374044.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):87-90 [9414101.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):85-100 [9457471.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):L81-6 [9458804.001]
  • [Cites] J Appl Toxicol. 1998 Sep-Oct;18(5):307-12 [9804429.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 1999 Sep-Oct;12(5):247-56 [10461093.001]
  • [Cites] FASEB J. 2005 Mar;19(3):311-30 [15746175.001]
  • [Cites] Exp Cell Res. 2005 Apr 15;305(1):51-62 [15777787.001]
  • [Cites] J Am Chem Soc. 2005 Mar 30;127(12):4388-96 [15783221.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):823-39 [16002369.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):66-73 [15970370.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Nitric Oxide. 2006 Mar;14(2):122-9 [16125421.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):341-9 [16507455.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):854-62 [16508635.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):295-6 [16598890.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):294-302 [16816381.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2393-5 [17023518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] Toxicol Lett. 2007 Jan 10;168(1):58-74 [17141434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2029-30 [17284585.001]
  • [Cites] Water Sci Technol. 2006;54(11-12):327-34 [17302336.001]
  • [Cites] Mutat Res. 2007 Apr 2;628(2):99-106 [17223607.001]
  • [Cites] Biomaterials. 2007 Jul;28(19):2946-58 [17379299.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2364-72 [17893867.001]
  • [Cites] Oncogene. 2008 Nov 27;27(56):7070-82 [18806824.001]
  • [Cites] Tumour Biol. 2000 Jan-Feb;21(1):11-20 [10601837.001]
  • [Cites] Toxicology. 2001 Aug 28;165(2-3):133-44 [11522371.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):869-82 [11891186.001]
  • [Cites] Proc Nutr Soc. 2002 Feb;61(1):123-30 [12002786.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Biomaterials. 2002 Sep;23(17):3757-64 [12109701.001]
  • [Cites] Toxicol In Vitro. 2002 Oct;16(5):629-35 [12206830.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):455-60 [12676598.001]
  • [Cites] J Biosci. 2003 Feb;28(1):51-5 [12682424.001]
  • [Cites] Pharmacol Ther. 2003 Jul;99(1):113-32 [12804702.001]
  • [Cites] Prog Lipid Res. 2003 Nov;42(6):463-78 [14559067.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L344-53 [14555462.001]
  • [Cites] Water Sci Technol. 2004;49(1):103-10 [14979544.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 1;37(7):916-25 [15336307.001]
  • [Cites] J Nanosci Nanotechnol. 2004 May;4(5):521-31 [15503438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1848-51 [1057174.001]
  • [Cites] Ann N Y Acad Sci. 1976;276:455-65 [1071971.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] Scand J Work Environ Health. 1987 Feb;13(1):47-51 [3495034.001]
  • (PMID = 19815711.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 15FIX9V2JP / titanium dioxide; 61512-21-8 / Thymosin; 77591-33-4 / thymosin beta(4); 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; D1JT611TNE / Titanium; G9481N71RO / Deoxyguanosine; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2774079
  •  go-up   go-down


57. Uludag M, Citgez B, Polat N: Inflammatory pseudo-tumour of the appendix and acute appendicitis: a case report. Acta Chir Belg; 2008 Jul-Aug;108(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudo-tumour of the appendix and acute appendicitis: a case report.
  • Inflammatory myofibroblastic tumour (IMT) is a rare benign lesion of unknown aetiology.
  • It was initially described in the lung, but it was subsequently recognised that virtually any anatomic location can be involved.
  • We presented a 20-year-old male patient with a diagnosis of IMT that caused acute appendicitis.
  • Being aware of such an entity and being careful in the differential diagnosis of the appendiceal masses, especially the large masses, may prevent overtreatment.
  • [MeSH-minor] Acute Disease. Adult. Appendicitis / etiology. Appendicitis / pathology. Appendicitis / surgery. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807601.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


58. Zheng QF, Dong B, Sun Y, DU H, Xiong HC, Wu N, Chen JF, Sun L, Ao J, Li JY, Ji JF, Yang Y: [Expression of TR4-associated protein in non-small cell lung cancer]. Beijing Da Xue Xue Bao; 2007 Oct 18;39(5):472-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TR4-associated protein in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression and significance of TR4-associated Protein (TRA16) in human non-small cell lung cancer (NSCLC) tissues.
  • METHODS: Immunohistochemistry (IHC) and tissue array were employed to investigate the expression of TRA16 in NSCLC cases of different pathological types, benign lung lesions and normal lung tissues.
  • RESULTS: The abundant expression of TRA16 was observed in nucleus and/or cytoplasm of NSCLC cells with a positive expression rate of 88.64%, whereas normal lung tissue and benign lung tumor rarely expressed TRA16 protein.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940562.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NR2C2AP protein, human; 0 / Nuclear Proteins; 0 / Repressor Proteins
  •  go-up   go-down


59. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M: Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch; 2007 Aug;451 Suppl 1:S51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data.
  • Neuroendocrine (NE) tumours of the lung include pure and mixed forms.
  • In the former group, a continuum of lesions is recognised ranging from benign typical carcinoids to atypical carcinoids (having a low-grade behaviour, although often associated with regional and distant metastases), to the highly aggressive poorly differentiated carcinomas of the small and large cell types.
  • In the mixed tumour group, the NE component is extensively represented in association with any of the non-small cell carcinoma subtypes (so-called combined carcinomas), or the NE component is restricted to a cell population scattered among adenocarcinoma cells (or more rarely within squamous or large cell carcinomas).
  • The molecular profile of NE tumours has been widely investigated to identify features helpful for the diagnosis, prognosis and even therapy for this special lung tumour category.
  • Specific chromosomal alterations, oncogene mutations and cell cycle molecule disregulation has been documented in NE tumours of the lung, as well as the expression of specific receptors or enzymes implicated in the response to biotherapies or to chemotherapeutic agents.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] Lab Invest. 1983 Nov;49(5):519-37 [6138458.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] J Pathol. 1998 Oct;186(2):151-6 [9924430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Brain Pathol. 2000 Jul;10(3):395-401 [10885658.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):434-9 [16872437.001]
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):317-322 [11494008.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1614-20 [2553880.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):838-44 [2394833.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6927-36 [17471231.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10680-5 [16322211.001]
  • [Cites] Thorax. 1995 May;50(5):551-4 [7541167.001]
  • [Cites] Lancet. 2004 Mar 6;363(9411):775-81 [15016488.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6908-14 [12362273.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1284-91 [8608504.001]
  • [Cites] J Biol Chem. 1980 Aug 10;255(15):7386-90 [7391086.001]
  • [Cites] Cancer Biol Ther. 2002 Jan-Feb;1(1):65-9 [12170765.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1148-55 [15343518.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):175-82 [11957142.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3971-9 [12124329.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5119-22 [10537285.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8423-32 [16166321.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1835-41 [17311257.001]
  • [Cites] Oncogene. 1998 Jul 30;17 (4):475-9 [9696041.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] Histopathology. 2005 Feb;46(2):195-201 [15693892.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Sep;64(3):413-21 [5054879.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1222-9 [15026805.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2104-9 [11391591.001]
  • [Cites] Lab Invest. 1988 Jul;59(1):5-24 [2839735.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):653-8 [7755151.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] Histopathology. 1990 Oct;17(4):353-8 [2124206.001]
  • [Cites] Expert Opin Investig Drugs. 2005 Mar;14(3):313-28 [15833062.001]
  • [Cites] Neuroendocrinology. 2007;85(1):54-60 [17310129.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):272-87 [17043625.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):109-17 [15788643.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3811-4 [13959775.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):4144-50 [6744325.001]
  • [Cites] Pediatr Pathol. 1993 Mar-Apr;13(2):165-80 [8464778.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):229-33 [11556750.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jan;37(1):16-22 [17060405.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):70-6 [16382115.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):787-97 [11787852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer. 2003 May 15;97(10):2487-97 [12733148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):600-7 [10091733.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):557-64 [16465412.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1259-67 [15154011.001]
  • [Cites] Lung Cancer. 2006 Nov;54(2):155-62 [16938365.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2832-9 [15837730.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):47-57 [10718213.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1013-21 [12133904.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):272-9 [9496831.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1678-87 [11313916.001]
  • (PMID = 17684766.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


60. Oremek GM, Sauer-Eppel H, Bruzdziak TH: Value of tumour and inflammatory markers in lung cancer. Anticancer Res; 2007 Jul-Aug;27(4A):1911-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of tumour and inflammatory markers in lung cancer.
  • The aim of this study was to evaluate the individual diagnostic utility of tumour and inflammatory markers in patients with different pulmonary diseases.
  • The usefulness of neuron-specific enolase (NSE), carcino-embryonic antigen (CEA), serum pro-gastrin releasing peptide (ProGRP) and CYFRA 21-1, as tumour markers, and C-reactive protein (CRP) and tumour necrosis factor-alpha (TNFalpha) as inflammatory markers for diagnosis, treatment and monitoring of patients with different pulmonary afflictions was investigated.
  • Serum samples were also obtained from 20 patients suffering from bronchitis, 20 with lung fibrosis and 30 with sarcoidosis.
  • Moreover, serum marker levels were analyzed in 139 patients with different pulmonary malignancies: 29 patients with adenocarcinoma, 30 patients with squamous cell carcinoma, 80 patients with small cell lung cancer (SCLC).
  • All tumour markers showed significantly elevated values in malignant diseases.
  • The levels of ProGRP in patients with benign diseases were significantly higher than those in the healthy group (35.4 +/- 6.6 compared with 21.3 +/- 9.2 pg/ml respectively).
  • The elevation was significantly higher than that of the benign reference group.
  • Serum CRP levels were significantly higher in patients with SCLC (38.5 +/- 7.6 mg/dl) than in the benign reference group.
  • In conclusion, when serum tumour markers are abnormally elevated in patients with lung cancer, CEA, CYFRA 21-1, NSE and ProGRP are useful clinical markers, good indicators of disease extent and may have important prognostic value.
  • [MeSH-major] Biomarkers, Tumor / blood. Inflammation / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / blood. Area Under Curve. C-Reactive Protein / analysis. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / diagnosis. Humans. Immunoassay. Keratin-19. Keratins / blood. Lung Diseases / blood. Lung Diseases / diagnosis. Peptide Fragments / blood. Peptides / blood. Phosphopyruvate Hydratase / blood. ROC Curve. Recombinant Proteins / blood. Sensitivity and Specificity. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649794.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / antigen CYFRA21.1; 0 / pro-gastrin-releasing peptide (31-98); 68238-35-7 / Keratins; 9007-41-4 / C-Reactive Protein; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


61. Nap RR, Meinardi JR, van den Berg G, Dullaart RP, de Vries J, Wolffenbuttel BH: [Long-term follow-up is indicated after surgery for a phaeochromocytoma]. Ned Tijdschr Geneeskd; 2006 May 13;150(19):1045-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrasound examination revealed a tumour in the right upper abdomen and a recurrence of phaeochromocytoma was diagnosed; an intact pregnancy was also found.
  • After a healthy son had been born by caesarian section, she underwent debulking of the large intra-abdominal lymph nodes and of two metastases in the lung.
  • Studies report recurrence ofphaeochromocytoma in 8-20% of cases, and such a recurrence may be either benign or malignant.
  • Factors predictive for recurrence are older age, a malignant primary tumour, tumour weight above 60 g, extra-adrenal origin of the tumour and peroperative tumour spill.
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733977.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Seoane J, Van der Waal I, Van der Waal RI, Cameselle-Teijeiro J, Antón I, Tardio A, Alcázar-Otero JJ, Varela-Centelles P, Diz P: Metastatic tumours to the oral cavity: a survival study with a special focus on gingival metastases. J Clin Periodontol; 2009 Jun;36(6):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A series of 39 patients were studied, analysing age, gender, primary tumour site, oral metastases site and histological type.
  • The most frequent sites for primary tumours were the kidney (20.5%), lung (20.5%) and breast (20.5%).
  • The average time between primary tumour diagnosis and appearance of the gingival metastases was 9.7+/-13.4 months.
  • Dental practitioners should suspect that gingival masses mimicking benign or inflammatory lesions may represent a sign of underlying malignant tumours.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Female. Follow-Up Studies. Humans. Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Male. Mandibular Neoplasms / secondary. Maxillary Neoplasms / secondary. Middle Aged. Neoplasms, Unknown Primary / pathology. Netherlands / epidemiology. Prognosis. Retrospective Studies. Sex Factors. Spain / epidemiology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508248.001).
  • [ISSN] 1600-051X
  • [Journal-full-title] Journal of clinical periodontology
  • [ISO-abbreviation] J. Clin. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Li CS, Cheng BC, Ge W, Gao JF: Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract; 2007 Mar;61(3):444-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate the individual and combined diagnostic value of five tumour markers in the elderly patients with pleural effusions.
  • Serum and pleural fluid levels of cytokeratin fragment 19 (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) were assayed in 32 elderly patients with malignant pleural effusions resulting from advanced lung cancer and in 30 elderly patients with benign pleural effusions by ELISA.
  • Serum levels of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 in patients with malignant pleural effusions were 12.84 +/- 6.48 microg/l, 22.07 +/- 11.25 microg/l, 65.74 +/- 30.26 kU/l, 56.32 +/- 25.6 kU/l and 71.86 +/- 31.45 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01).
  • Pleural fluid levels of CYFRA21-1, CA15-3, CA19-9 and CA125 except NSE in patients with malignant pleural effusions were 18.64 +/- 8.15 microg/l, 59.31 +/- 27.35 kU/l, 48.24 +/- 21.56 kU/l and 62.16 +/- 27.79 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01).
  • The parallel combined testing of five tumour markers in serum increased the diagnostic sensitivity to 90.6%, and serial combined testing increased the diagnostic specificity to 93.3%.
  • The sensitivity (%) and specificity (%) of these tumour markers in pleural fluid were as follows: CYFRA21-1, 84.4/90; CA15-3, 62.5/73.3; CA19-9, 37.5/66.7; CA125, 56.3/70; for differentiating malignant effusions from benign effusions.
  • Serum and pleural fluid levels of the five tumour markers shows certain values in the diagnosis and differentiate diagnosis for malignant pleural effusions in the elderly patients from benign.
  • The combined assay of five tumour markers in serum and the CYFRA21-1 combined with CA15-3 in pleural fluid were helpful and can increase the sensitivity and specificity in diagnosing malignant pleural effusions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. CA-125 Antigen / metabolism. CA-19-9 Antigen / metabolism. Diagnosis, Differential. Female. Humans. Keratin-19. Keratins / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Phosphopyruvate Hydratase / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313612.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Keratin-19; 0 / Mucin-1; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


64. Floyd HS, Jennings-Gee JE, Kock ND, Miller MS: Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog; 2006 Jul;45(7):506-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
  • Mutations in Ki-ras occur in approximately 30-50% of patients with adenocarcinoma (AC) of the lung.
  • We previously reported the development of a bitransgenic mouse model that expressed the human Ki-ras(G12C) allele in a lung-specific, tetracycline-inducible manner and gave rise to benign lung tumors.
  • In the current study, these benign tumors, which represent relatively early lesions in neoplastic progression, were analyzed for molecular alterations secondary to mutant Ki-ras expression to determine the gene(s) that contribute to adenoma (AD) development.
  • Tumors were removed following doxycycline (DOX) treatment for 9 and 12 mo and examined for alterations in cell-cycle regulatory genes.
  • All of the tumors examined exhibited a mean reduction of approximately fivefold for the retinoblastoma gene (P < 0.02).
  • Increased expression of both p19(Arf) and survivin were detected in a majority of the tumors examined (P < 0.01 and 0.001, respectively), but no change in cyclin D1 RNA expression was observed.
  • A subset of the lung tumors (8/28) displayed reduced levels of p16(Ink4a) expression (P = 0.02).
  • Immunohistochemical analysis confirmed the upregulation of p19(Arf) and survivin in all 10 of the lung tumors examined.
  • However, increased staining for cyclin D1 was observed in the tumor tissue.
  • In addition, increased levels of activated p53 were found in lung tumor tissues stained with an anti-phospho-p53 antibody, while an absence of staining was observed with an anti-phospho-pRb antibody in both normal control and tumor tissue.
  • Analysis of the methylation status of p16(Ink4a) by methylation-specific PCR (MSP) demonstrated that seven of eight tumors exhibiting decreased expression of p16(Ink4a) had at least partial methylation of the promoter region.
  • These data thus identify alterations in specific genes and pathways that combine with the mutation in Ki-ras to promote the formation of benign lung tumors and suggest potential targets for the development of novel chemotherapeutic and chemopreventive agents during the early stages of lung tumor progression.
  • [MeSH-major] Genes, ras / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. ras Proteins / genetics
  • [MeSH-minor] Animals. Base Sequence. Cell Cycle / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Primers. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Disease Models, Animal. Humans. Mice. Mice, Transgenic. Retinoblastoma Protein / genetics


65. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • MN/CA9 has proved to be a valuable marker in many cancers such as lung, breast, colon, kidney, etc.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


66. Cheng S, Edmonds E, Ben-Gashir M, Yu RC: Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol; 2008 May;33(3):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically the salient feature is a subcorneal accumulation of neutrophils, suggesting the presence of chemoattractants such as tumour necrosis factor (TNF)alpha in the uppermost epidermis.
  • Cases in association with pyoderma gangrenosum, benign monoclonal IgA gammopathy and multiple myeloma are well documented.
  • There are anecdotal reports of SCPD associated with other internal malignancies such as chronic lymphocytic leukaemia, thymoma, apudoma and epidermoid carcinoma of the lung.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Blister / etiology. Dapsone / therapeutic use. Diagnosis, Differential. Female. Humans. Male. Paraproteinemias / diagnosis. Treatment Outcome

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for subcorneal pustular dermatosis .
  • Hazardous Substances Data Bank. DAPSONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18355359.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunoglobulin A; 8W5C518302 / Dapsone
  • [Number-of-references] 30
  •  go-up   go-down


67. Wong CW, El-Jack S, Edwards C, Patel H: Primary cardiac angiosarcoma: morphologically deceptive benign appearance and potential pitfalls in diagnosis. Heart Lung Circ; 2010 Aug;19(8):473-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac angiosarcoma: morphologically deceptive benign appearance and potential pitfalls in diagnosis.
  • Cardiac angiosarcoma is the most common malignant primary cardiac tumour.
  • Histological diagnosis was elusive underscoring the potential difficulty in differentiating this tumour from normal vascular endothelium.
  • [MeSH-major] Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Pericardial Effusion / etiology

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20457008.001).
  • [ISSN] 1444-2892
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


68. Filosso PL, Asioli S, Ruffini E, Rovea P, Macri' L, Sapino A, Bretti S, Lyberis P, Oliaro A: Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura. Lung Cancer; 2009 Apr;64(1):117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura.
  • Although usually benign, malignant SFTs are described, and they are often associated with large, necrotic and locally invasive tumours.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046791.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


69. Jha NK, Khouri M, Murphy DM, Salustri A, Khan JA, Saleh MA, Von Canal F, Augustin N: Papillary fibroelastoma of the aortic valve--a case report and literature review. J Cardiothorac Surg; 2010;5:84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of primary cardiac tumour ranges from 0.0017-0.28% and papillary fibroelastoma is rare but not uncommon benign cardiac neoplasm.
  • The differential diagnosis considered was a thrombus, myxoma, Lambl's excrescence and infective vegetation.
  • The surgical management included a prompt resection of the tumour on cardiopulmonary bypass avoiding injury to the aortic valve.
  • Also, possibility of this diagnosis should be kept in mind while managing cardiac or valvular tumours.
  • [MeSH-major] Aortic Valve. Fibroma / diagnosis. Heart Neoplasms / diagnosis. Heart Valve Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Heart Inst J. 2009;36(2):160-3 [19436815.001]
  • [Cites] J Cardiothorac Surg. 2009;4:28 [19570232.001]
  • [Cites] Cardiovasc Ultrasound. 2009;7:43 [19725951.001]
  • [Cites] Ann Acad Med Singapore. 2009 Oct;38(10):926-7 [19890592.001]
  • [Cites] J Clin Pathol. 2009 Dec;62(12):1066-70 [19946092.001]
  • [Cites] Asian Cardiovasc Thorac Ann. 2010 Feb;18(2):174-6 [20304854.001]
  • [Cites] Can J Cardiol. 2007 Mar 15;23(4):301-2 [17380224.001]
  • [Cites] Ann Clin Lab Sci. 2001 Jul;31(3):291-6 [11508834.001]
  • [Cites] Am Heart J. 2003 Sep;146(3):404-10 [12947356.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2003 Aug;9(4):270-3 [13129429.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):106-10 [9869763.001]
  • [Cites] Ann Thorac Surg. 2005 Nov;80(5):1712-8 [16242444.001]
  • [Cites] Angiology. 2008 Oct-Nov;59(5):625-8 [18388078.001]
  • (PMID = 20950491.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2965711
  •  go-up   go-down


70. Azad NS, Ahmad Z, Ahsan A, Fatimi S, Ahmed R, Kayani N, Pervez S, Hasan SH: Thymoma : a clinicopathologic association of world health organization histologic subtype and invasive behaviour. J Coll Physicians Surg Pak; 2007 Nov;17(11):658-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Capsular invasion as well as extension into neighboring structures such as perithymic fat, pleura, pericardium, lung etc. was noted on morphology.
  • RESULTS: A total of 62 cases were diagnosed as Thymic Epithelial Tumors (TET).
  • However, morphologically benign looking thymomas can behave aggressively.
  • Hence, tumour stage, extent of resection and histology should be combined to predict the clinical behaviour of thymomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070571.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


71. Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR: The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol; 2008 Jul;63(7):756-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
  • AIM: To assess the clinical value of dual time point 2-[(18)F]-fluoro-2-deoxy-d-glucose positron emission tomography ((18)F-FDG PET) imaging for the differentiation between malignant and benign lesions.
  • MATERIALS AND METHODS: Ninety-six patients (28 patients with primary lung cancer, 18 patients with digestive system carcinoma, 13 patients with other malignant tumours, and 37 patients with benign lesions) underwent FDG-PET/CT at two time points: examination 1 at 45-55 min and examination 2 at 160+/-24 (150-180) min after the intravenous injection of 233+/-52 (185-370)MBq (18)F-FDG.
  • RESULTS: The lesions in 24 of 28 (86%) patients with primary lung cancer had an SUVmax > or = 2.5 at examination 1.
  • The lesions in the other four patients with primary lung tumour had SUVmax values between 1.5 and 2.5 at examination 1, which were considered as suspected positive, increased SUVmax values were observed in three of these patients at examination 2.
  • Only 12 of 37 (32%) patients with benign lesions showed SUVmax values > or = 2.5 at examination 1 and nine patients with benign lesions had SUVmax values > or = 2.5 in examination 2.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Digestive System Neoplasms / radiography. Digestive System Neoplasms / radionuclide imaging. Female. Humans. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Male. Middle Aged. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555033.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Jain S, Agrawal D, Shah T, Udwadia ZE: Resection of a endobronchial hamartoma by electrocautery and argon plasma ablation via fiberoptic bronchoscopy. Indian J Chest Dis Allied Sci; 2006 Jul-Sep;48(3):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial hamartoma is a rare benign tumour of the lung that may present with bronchial obstruction.

  • MedlinePlus Health Information. consumer health - Bronchial Disorders.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18610683.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  •  go-up   go-down


73. Klöppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):15-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour biology and histopathology of neuroendocrine tumours.
  • In the lung they are called carcinoid and small/large-cell neuroendocrine carcinomas.
  • Their clinical behaviour--ranging from benign and low-grade to high-grade malignancy--can be predicted on the basis of clinicopathological criteria.
  • [MeSH-major] Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma / classification. Carcinoma / diagnosis. Carcinoma / genetics. Carcinoma / pathology. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neurosecretory Systems / cytology. Prognosis. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / genetics. Respiratory Tract Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382263.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


74. Rotger A, Trifirò G, Travaini LL, de Cicco C, Paganelli G: Carcinoma, tuberculosis and elastofibroma in one patient: is [18F]FDG-PET/CT helpful? Rev Esp Med Nucl; 2009 Jan-Feb;28(1):22-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a woman with persistent dorsal pain and two solid lung lesions documented on multidetector CT which showed concomitant [18F]FDG uptake.
  • Incidentally, the patient also had an elastofibroma dorsi, a rare benign tumour which can also be a possible source of false results in the PET exam.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Diagnostic Errors. Fibroma / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Tomography, Spiral Computed. Tuberculosis, Lymph Node / radionuclide imaging. Tuberculosis, Pulmonary / radionuclide imaging
  • [MeSH-minor] Aged. Back Pain / etiology. Combined Modality Therapy. False Positive Reactions. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Incidental Findings. Lymphatic Metastasis. Neoplasm Staging. Radiopharmaceuticals. Tuberculoma / radionuclide imaging

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232174.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. McIntosh J, Sylvester PA, Virjee J, Callaway M, Thomas MG: Pulmonary staging in colorectal cancer--is computerised tomography the answer? Ann R Coll Surg Engl; 2005 Sep;87(5):331-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient underwent colectomy, and 2 patients who had primary lung tumours as opposed to metastases also underwent colectomies.
  • In addition, one of the patients underwent multiple, non-diagnostic thoracic investigations prior to a diagnosis of sarcoidosis being made and then proceeding to surgery.
  • An independent consultant radiologist reviewed seven out of the nine CXRs of patients with an abnormality on thoracic CT without knowledge of the clinical diagnosis, and reported three of the CXRs to be normal.
  • However, CT is likely to identify more benign radiological abnormalities than CXR alone, and investigations should not occur to the detriment of treating the primary tumour.
  • [MeSH-major] Colorectal Neoplasms. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasm Staging / standards. Prospective Studies. Sensitivity and Specificity


76. Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, Ramirez J, Filella X: Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol; 2008;29(6):371-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.
  • Tumor marker serum levels were prospectively studied in 289 patients with suspected, but unconfirmed, lung cancer and in 513 patients with lung cancer [417 non-small cell lung cancer (NSCLC) patients and 96 small cell lung cancer (SCLC) patients].
  • In patients with benign disease, abnormal serum levels were found for the following tumor markers: CEA (in 6.6% of patients); CA 19.9 (6.2%); CA 125 (28.7%); NSE (0.7%); CYFRA (8.7%); TAG-72.3 (4.2%); SCC (3.5%), and CA 15.3 (3.5%).
  • Excluding patients with renal failure or liver diseases, tumor marker specificity improved with abnormal levels in 0.5% for NSE, 0.9% for SCC, 2.8% for CEA, CA 15.3 and TAG-72.3, 3.8% for CA 19.9, 4.2% for CYFRA and 21.4% for CA 125.
  • Tumor marker sensitivity was related to cancer histology and tumor extension.
  • Likewise, significantly higher CEA (p < 0.0001), TAG-72.3 (p < 0.001), CA 15.3 (p < 0.0001) and CA 125 (p < 0.01) were found in adenocarcinomas than in squamous tumors.
  • Using a combination of 3 tumor markers (CEA, CYFRA 21-1 in all histologies, SCC in squamous tumors and CA 15.3 in adenocarcinomas), a high sensitivity may be achieved in all histological types.
  • Tumor markers may be useful in the histological differentiation of NSCLC and SCLC.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Lung Neoplasms / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19060513.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Roberge D, Hickeson M, Charest M, Turcotte RE: Initial McGill experience with fluorodeoxyglucose pet/ct staging of soft-tissue sarcoma. Curr Oncol; 2010 Nov;17(6):18-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue sarcoma spreads predominantly to the lung.
  • Ewing sarcoma, rhabdomyosarcoma, and gastrointestinal stromal tumour were excluded, as were cases in which patients underwent imaging for follow-up, response assessment, or recurrence.
  • In 21% of cases, the primary tumour had been removed (by excisional biopsy or unplanned excision) before staging.
  • Of all tumours, 81% were intermediate or high grade (Fédération Nationale des Centres de Lutte Contre le Cancer grades 2-3).
  • The primary tumour was stage T2b in 69% of cases.
  • Two incidental benign parotid tumours were found.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151405.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993434
  • [Keywords] NOTNLM ; Soft-tissue sarcoma / positron-emission tomography / staging
  •  go-up   go-down


78. Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, Cañamero M, Collado M, Salas C, Serrano M, Moscat J, Diaz-Meco MT: Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J; 2008 Aug 20;27(16):2181-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis.
  • The atypical PKC-interacting protein, Par-4, inhibits cell survival and tumorigenesis in vitro, and its genetic inactivation in mice leads to reduced lifespan, enhanced benign tumour development and low-frequency carcinogenesis.
  • Here, we demonstrate that Par-4 is highly expressed in normal lung but reduced in human lung cancer samples.
  • We show, in a mouse model of lung tumours, that the lack of Par-4 dramatically enhances Ras-induced lung carcinoma formation in vivo, acting as a negative regulator of Akt activation.
  • We also demonstrate in cell culture, in vivo, and in biochemical experiments that Akt regulation by Par-4 is mediated by PKCzeta, establishing a new paradigm for Akt regulation and, likely, for Ras-induced lung carcinogenesis, wherein Par-4 is a novel tumour suppressor.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4689-98 [12970181.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):67-78 [14749127.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Cell Growth Differ. 1994 Apr;5(4):457-66 [8043520.001]
  • [Cites] Cell. 1996 Sep 6;86(5):777-86 [8797824.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6945-56 [8943350.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] Oncogene. 1998 Jul 23;17(3):313-25 [9690513.001]
  • [Cites] Genomics. 1998 Oct 15;53(2):241-3 [9790775.001]
  • [Cites] EMBO J. 2004 Nov 24;23(23):4595-605 [15526032.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] EMBO Rep. 2005 Jun;6(6):577-83 [15877079.001]
  • [Cites] Mol Cell. 2005 Oct 7;20(1):33-44 [16209943.001]
  • [Cites] Circ Res. 2006 Jan 6;98(1):111-8 [16306447.001]
  • [Cites] Cell Death Differ. 2006 May;13(5):702-11 [16322752.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):355-61 [16673382.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] J Exp Med. 2006 Oct 30;203(11):2551-62 [17060474.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1927-34 [17332319.001]
  • [Cites] Mol Cell. 2002 Jul;10(1):151-62 [12150915.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38021-8 [12149249.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] EMBO Rep. 2003 Mar;4(3):307-12 [12634851.001]
  • [Cites] Cell Cycle. 2003 Mar-Apr;2(2):71-2 [12695647.001]
  • [Cites] Oncogene. 2003 Apr 24;22(16):2432-42 [12717420.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):487-502 [17419990.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Proteomics. 2008 Mar;8(5):994-9 [18324724.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6362-9 [10562548.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7265-73 [10602480.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):771-80 [11684013.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6174-86 [12917339.001]
  • (PMID = 18650932.001).
  • [ISSN] 1460-2075
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI072581; United States / NIAID NIH HHS / AI / R01-AI072581
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Thrombin; 0 / Transcription Factor RelA; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / protease-activated receptor 4; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / protein kinase C zeta; EC 2.7.11.13 / Protein Kinase C; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2519103
  •  go-up   go-down


79. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 01;28(13):2159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoassay. Mass Screening / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Medscape Womens Health. 1996 Nov;1(11):3 [9746655.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


80. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S: Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine. Int J Cancer; 2010 Mar 1;126(5):1047-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine.
  • Lung cancer is the most important cause of death among neoplastic diseases worldwide, and cigarette smoke (CS) is the major risk factor for cancer.
  • Exposure to CS resulted in a high incidence and multiplicity of benign lung tumors and in significant increases of malignant lung tumors and other histopathological alterations.
  • In conclusion, the proposed experimental model provides convincing evidence that it is possible to prevent CS-induced lung cancer by means of dietary and pharmacological agents.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816928.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] None / None / / N01 CN053301; United States / NCI NIH HHS / CN / N01 CN053301; United States / NCI NIH HHS / CA / N01CN53301; United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Isothiocyanates; 0 / Tobacco Smoke Pollution; 51333-22-3 / Budesonide; 6U7TFK75KV / phenethyl isothiocyanate; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ NIHMS163521; NLM/ PMC4909837
  •  go-up   go-down


81. Quaia E, Tona G, Gelain F, Lubin E, Pizzolato R, Boscolo E, Bussoli L: Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection. Acta Radiol; 2008 Nov;49(9):995-1004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
  • BACKGROUND: Accurate staging is necessary to determine the appropriate therapy in patients with lung cancer.
  • Few studies have compared integrated fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and contrast-enhanced CT in the characterization and staging of pulmonary tumors considered eligible for surgical resection.
  • PURPOSE: To compare 18F-FDG PET/CT with standard contrast-enhanced CT for the diagnosis and staging of lung neoplasms eligible for surgical resection.
  • MATERIAL AND METHODS: Seventy-six consecutive patients (56 male, 20 female; mean age+/-SD, 63.4+/-20 years) with 84 pulmonary tumors suspected for malignancy and considered eligible for surgical resection were prospectively enrolled.
  • Seventy-three malignant (65 non-small-cell lung carcinomas, one small-cell lung cancer, two carcinoids, and five metastases) and 11 benign lung tumors (three hamartomas, two sarcoidosis, one amyloidosis, one Wegener granulomatosis, one tuberculosis, and three areas of scarring) were finally diagnosed by histology.
  • Tumor staging was based on the revised American Joint Committee on Cancer.
  • CONCLUSION: In patients with lung neoplasms considered eligible for surgical resection, (18)F-FDG PET/CT versus contrast-enhanced CT revealed higher sensitivity in nodal staging, but lower specificity both in lesion characterization and nodal staging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Contrast Media. Female. Humans. Image Enhancement. Lung Diseases / diagnosis. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18651256.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Roy AE, Wells P: Volume definition in radiotherapy planning for lung cancer: how the radiologist can help. Cancer Imaging; 2006;6:116-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volume definition in radiotherapy planning for lung cancer: how the radiologist can help.
  • Effective treatment for carcinoma of the lung remains one of the biggest challenges in oncology.
  • This greater accuracy of target volume definition facilitates a reduction in the radiation dose to normal tissues, allowing for dose escalation to the tumour.
  • Conventional CT has limitations in term of distinguishing between benign and malignant tissues, e.g. the size criteria for involved lymph nodes.
  • This article aims to briefly explain the planning process involved in irradiating lung cancers, highlight problematic areas and suggest ways in which co-operation with radiologists may improve the delivery of radiotherapy and therefore the treatment outcomes for this group of patients.
  • [MeSH-major] Lung Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) International Cancer Imaging Society.
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):170-8 [16111586.001]
  • [Cites] Radiother Oncol. 2000 Jun;55(3):317-24 [10869746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1015-24 [11072158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):681-5 [11395236.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):27-36 [11830310.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Aug;12(2):224-7 [9288511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1336-44 [14630271.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] J Thorac Imaging. 1991 Apr;6(2):28-31 [1856899.001]
  • [Cites] Radiology. 1994 Dec;193(3):795-800 [7972827.001]
  • [Cites] Chest. 1997 Jun;111(6):1718-23 [9187199.001]
  • [Cites] Radiother Oncol. 2002 Jan;62(1):37-49 [11830311.001]
  • (PMID = 16966067.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1693758
  •  go-up   go-down


83. Sharma KB: Spontaneous expectoration of lung tumour mass. CMAJ; 2005 Apr 26;172(9):1182
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous expectoration of lung tumour mass.
  • [MeSH-major] Cough. Histiocytoma, Benign Fibrous / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Fatal Outcome. Foot Diseases / pathology. Hemoptysis / etiology. Humans. Lung / radiography. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1980 Jan 1;45(1):167-78 [6243239.001]
  • [Cites] Cancer Invest. 2001;19(1):23-7 [11291552.001]
  • [Cites] Chest. 1999 Feb;115(2):595-8 [10027470.001]
  • [Cites] Chest. 1994 Feb;105(2):454-7 [8306746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [CommentIn] CMAJ. 2005 Nov 8;173(10):1206 [16275975.001]
  • (PMID = 15851710.001).
  • [ISSN] 1488-2329
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC557068
  •  go-up   go-down


84. Bodtger U, Pedersen JH, Skov BG, Clementsen P: Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm. Clin Respir J; 2009 Apr;3(2):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm.
  • BACKGROUND: Low forced expiratory volume (FEV(1)) and low performance status usually preclude surgical treatment of lung neoplasms.
  • METHODS: A case report of an 83-year-old women with progressing dyspnoea secondary to a huge left-side neoplasm.
  • RESULTS: Work-up reveal an FEV(1) of 0.4 L, and a giant solitary fibrous tumor of the pleura.
  • The tumor was surgically removed in toto without complications: weighting approximately 3 kg, and benign histology.
  • CONCLUSION: Safe and curative surgery is possible in patients with extrapulmonal neoplasm despite poor FEV(1).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dyspnea / diagnosis. Dyspnea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Postoperative Care / methods. Preoperative Care / methods. Radiography, Thoracic. Severity of Illness Index. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298386.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Cascini GL, Cuccurullo V, Mansi L: The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging; 2010 Feb;54(1):24-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.
  • Because of this uptake clinical indications can be found also in active benign diseases, as Grave's ophthalmopathy, rheumatoid arthritis, histiocitosis, sarcoidosis, idiopatic pulmonary fibrosis.
  • Moreover, these cells can also determine the OCT in vivo uptake in tumours non expressing in vitro SSR, as non-snall cell lung cancer (NSCLC).
  • Because of a different kinetic respect to SCLC a differential histotype diagnosis could be obtained.
  • Finally a relevant clinical role can be defined in the a priori recruitment and as marker of therapeutic efficacy in all the therapeutic strategies utilizing SSR, both in malignant and benign diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168284.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / indium-111-octreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 98
  •  go-up   go-down


86. Khadilkar UN, Kumar S, Prabhu PP, Kamath M: Mucoepidermoid carcinoma of lung: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of lung: a case report.
  • Mucoepidermoid lung tumours are uncommon neoplasms comprising of 0.2% of all the lung tumours and historically included under the term bronchial adenomas.
  • This is a case report of a bronchial tumour in the hilar region present since 3 years.
  • The neoplasm could be easily classified as a mucoepidermoid tumour of low malignant potential, as it resembled the histologically identical lesion in the main salivary glands.
  • The case is reported for its rarity and for the histological evaluation of the malignant potential in an apparently clinically benign neoplasm.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Lung / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883135.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


87. Listewnik MH, Birkenfeld B, Chosia M, Elbl B, Niedziałkowska K, Sawrymowicz M: The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases. Endokrynol Pol; 2010 Sep-Oct;61(5):454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases.
  • INTRODUCTION: Radioiodine treatment (RT) of benign thyroid diseases is a well-known, safe, and effective treatment.
  • Suspicious thyroid lesion results were found in 9 patients (8 F, 1 M), aged 46-73 (average 56 years) followed up for 3-57 months after RT: papillary cancer in two patients, Hürthle cell tumour in one patient, and suspicious cells in two patients (with benign lesions on postoperative histopathology).
  • A follicular tumour in FNAB was suspected in two cases (no data about the first, and the second with lung cancer was not operable).
  • CONCLUSIONS: Malignant thyroid lesions in patients after RT due to benign thyroid diseases are seldom detected.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnostic imaging. Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / etiology. Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic. Aged. Biopsy, Fine-Needle. Carcinoma. Causality. Female. Follow-Up Studies. Humans. Incidence. Lung Neoplasms / diagnosis. Lung Neoplasms / epidemiology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049457.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Thyroid cancer, Hurthle cell; Thyroid cancer, papillary
  •  go-up   go-down


88. Sauer T, Pedersen MK, Ebeltoft K, Naess O: Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology; 2005 Aug;16(4):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The material consisted of 52 air-dried smears from fine needle aspirates of breast carcinomas, both primary and metastatic and smears from seven benign lesions.
  • The degree of staining was recorded as negative, reduced or full, with full expression meaning equivalent to the staining pattern found in the fibroadenomas used as benign control.
  • In cases with reduced expression, the percentage of stained cells were usually high, and no smear showed <50% stained tumour cells.
  • Claudin-7 expression showed a significant correlation (P < 0.05) with grading, locoregional and distant metastases, nodal involvement and cellular cohesion in invasive carcinomas, but not with tumour size or subtype.
  • CONCLUSION: Reduced expression of Claudin-7 correlated with higher tumour grade, metastatic disease, including loco-regional recurrences and with cellular discohesion.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Membrane Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048505.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN7 protein, human; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


89. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schäfers HJ, Sybrecht GW, Kirsch CM: Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging; 2006 Jan;33(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
  • PURPOSE: The differentiation of recurrent lung cancer and post-therapeutic changes remains a problem for radiological imaging, but FDG-PET allows biological characterisation of tissues by visualising glucose metabolism.
  • We evaluated the diagnostic performance and prognostic impact of FDG-PET in cases of suspected relapse of lung cancer.
  • METHODS: In 62 consecutive patients, 73 FDG-PET scans were performed for suspected recurrence after surgical therapy of lung cancer.
  • PET results were compared with the final diagnosis established by biopsy or imaging follow-up.
  • SUV in recurrent tumour was higher than in benign post-therapeutic changes (10.6+/-5.1 vs 2.1+/-0.6, p<0.001).
  • Median survival was longer for patients with lower FDG uptake in recurrent tumour (SUV<11: 18 months, SUV > or = 11: 9 months, p<0.01).
  • SUV in recurrent tumour was identified as an independent prognostic factor (p<0.05).
  • CONCLUSION: FDG-PET accurately detects recurrent lung cancer.
  • SUV in recurrent tumour is an independent prognostic factor.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / surgery. Fluorodeoxyglucose F18. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / surgery. Neoplasm Recurrence, Local / diagnostic imaging

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pneumologie. 2000 Feb;54(2):49-53 [10731756.001]
  • [Cites] Front Radiat Ther Oncol. 2002;37:26-33 [11764664.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1640-6 [15471827.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3255-60 [15310769.001]
  • [Cites] J Nucl Med. 1995 May;36(5):788-93 [7738649.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):918-24 [9731895.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):769-74 [10701623.001]
  • [Cites] Eur Respir J. 1999 Dec;14 (6):1376-80 [10624770.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1605-13 [11696628.001]
  • [Cites] J Thorac Imaging. 1997 Jul;12(3):200-8 [9249678.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):25-30 [1324898.001]
  • [Cites] Radiology. 1994 May;191(2):379-82 [8153309.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1771-6 [7965154.001]
  • [Cites] Nucl Med Commun. 2000 Aug;21(8):707-14 [11039452.001]
  • [Cites] J Nucl Med. 2002 Jul;43(7):871-5 [12097455.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(1):73-8 [1529302.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Jul;110(1):130-9; discussion 139-40 [7609536.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9 [15573074.001]
  • [Cites] Chest. 2000 Dec;118(6):1621-5 [11115449.001]
  • [Cites] Pneumologie. 2000 Aug;54(8):361-71 [11008479.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):363-6 [11505287.001]
  • [Cites] J Nucl Med. 2002 Jan;43(1):39-45 [11801701.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] J Nucl Med. 1994 Aug;35(8):1308-12 [8046485.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3201-6 [10506619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1495-512 [7635795.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1285-92 [12663716.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Jun;48(2):119-42 [15243408.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14 ):2651-7 [12860940.001]
  • [Cites] Eur Respir J. 2002 Mar;19(3):464-8 [11936523.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Jun;149(6):1635-9 [7516252.001]
  • [Cites] Nucl Med Commun. 2002 Sep;23 (9):865-70 [12195091.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):531-40 [15337482.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):935-8; discussion 938-40 [12146993.001]
  • [Cites] J Nucl Med. 2002 May;43(5):635-9 [11994527.001]
  • (PMID = 16151765.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Hu WD, Liao MY, Chen JK: [Clinical analysis of solitary pulmonary nodule measuring less than 10 mm]. Ai Zheng; 2006 Feb;25(2):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Lung cancer is a malignant disease with high incidence and mortality, and its prognosis is to large degree determined by early diagnosis and treatment.
  • X-ray chest film and computed tomography (CT) are important means to discover and diagnose lung cancer.
  • The differences between benign and malignant lesions were compared.
  • Imaging features of SPN of lung cancer were summarized.
  • RESULTS: Of the 102 cases of SPN measuring less than 10 mm, 66 (64.7%) were benign lesions, 25 (24.5%) were primary lung cancer, and 11 (10.8%) were metastatic lung cancer.
  • The benign lesions included inflammatory pseudotumor, benign tumor, lung tuberculosis, and so on.
  • Primary lung cancers, including 6 advanced cases (stage IIA and higher stage), had several radiological features different from benign nodules, such as ill-defined margins, speculation, bronchus or vessel involvement.
  • Also, the enhanced CT value was higher in malignant nodules than in benign nodules except inflammation pseudotumor.
  • The SPNs of metastatic lung cancer had similar radiologic features to those of primary lung cancer.
  • CONCLUSION: SPNs measuring less than 10 mm are mainly composed of benign lung tumor and primary lung cancer.
  • [MeSH-major] Lung Neoplasms. Solitary Pulmonary Nodule
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Lung Diseases / pathology. Lung Diseases / radiography. Male. Middle Aged. Retrospective Studies. Smoking. Tomography, X-Ray Computed / methods. Tuberculosis, Pulmonary / pathology. Tuberculosis, Pulmonary / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480590.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Stojsić J, Milenković B, Radojicić J, Percinkovski M: [Alveolar adenoma -- a rare lung tumour]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):461-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar adenoma -- a rare lung tumour].
  • INTRODUCTION: Alveolar adenoma belongs to the group of benign epithelial tumours.
  • CONCLUSION: Alveolar adenoma is a rare benign lung tumour, most frequently presented as a solitary pulmonary nodule.
  • After complete surgery, the tumour neither relapses nor malignantly alters.
  • [MeSH-major] Adenoma / diagnosis. Lung Neoplasms / diagnosis. Solitary Pulmonary Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929540.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


92. Myers KA, Wong KK, Tipple M, Sanatani S: Benign cardiac tumours, malignant arrhythmias. Can J Cardiol; 2010 Feb;26(2):e58-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign cardiac tumours, malignant arrhythmias.
  • Sudden cardiac death attributable to the tumour occurred in two children.
  • Most PCTs are considered benign; however, the development of malignant arrhythmias may complicate the management of these tumours in some patients.
  • [MeSH-minor] Child. Diagnosis, Differential. Echocardiography. Electrocardiography, Ambulatory. Fatal Outcome. Follow-Up Studies. Heart Atria. Heart Ventricles. Humans. Infant, Newborn. Magnetic Resonance Imaging. Male. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Pathol. 1999 Mar-Apr;8(2):109-12 [10724508.001]
  • [Cites] Pediatr Cardiol. 2000 Jul-Aug;21(4):299-316 [10865003.001]
  • [Cites] Pediatr Cardiol. 2000 Jul-Aug;21(4):317-23 [10865004.001]
  • [Cites] Pacing Clin Electrophysiol. 2001 Nov;24(11):1699-700 [11816644.001]
  • [Cites] Am J Forensic Med Pathol. 2002 Mar;23(1):83-9 [11953502.001]
  • [Cites] Circulation. 2004 Apr 27;109(16):1994-2000 [15051640.001]
  • [Cites] Cardiovasc Pathol. 2008 Jul-Aug;17(4):193-8 [18402818.001]
  • [Cites] J Cardiovasc Electrophysiol. 1999 Aug;10(8):1033-44 [10466482.001]
  • [Cites] Turk J Pediatr. 2006 Apr-Jun;48(2):172-4 [16848122.001]
  • [Cites] J Heart Lung Transplant. 2007 Jun;26(6):639-41 [17543790.001]
  • [Cites] Pediatr Cardiol. 2008 Jan;29(1):223-6 [17849072.001]
  • [Cites] Circulation. 2008 May 27;117(21):e350-408 [18483207.001]
  • [Cites] Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 1):138-9 [9990615.001]
  • (PMID = 20151061.001).
  • [ISSN] 1916-7075
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2851394
  •  go-up   go-down


93. Klenke FM, Merkle T, Fellenberg J, Abdollahi A, Huber PE, Gebhard MM, Ewerbeck V, Sckell A: A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim; 2005 Oct;39(4):377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although up to 85% of the most frequently occurring malignant solid tumours, such as lung and prostate carcinomas, metastasize into the bone, and despite the knowledge that a tumour's course may be altered by its surrounding tissue, there is no adequate experimental model available enabling the investigation of orthotopically grown bone tumours in vivo.
  • Intravital microscopy is an internationally accepted experimental method, used in various acute and chronic animal models, that enables qualitative and quantitative analysis of the angiogenesis, microcirculation, growth behaviour, etc. of various benign and malignant tissues.
  • Severe combined immunodeficient mice were fitted with a cranial window preparation where the calvaria served as the site for orthotopic implantation of the solid human tumours Saos-2 osteosarcoma (primary) and A 549 lung carcinoma and PC-3 prostate carcinoma (secondary).
  • Histological assessment confirmed the data obtained in vivo, showing typical tumour growth with infiltration of the surrounding osseous and soft tissues.
  • This novel model serves as a valuable tool in understanding the biology of primary and secondary bone tumours in physiological and pathophysiological situations, with implications for the most areas of tumour therapy such as chemotherapy, radiation and antiangiogenesis.
  • [MeSH-minor] Animals. Lung Neoplasms / pathology. Male. Mice. Mice, SCID. Microscopy, Fluorescence. Microscopy, Video. Neoplasm Transplantation. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197704.001).
  • [ISSN] 0023-6772
  • [Journal-full-title] Laboratory animals
  • [ISO-abbreviation] Lab. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


94. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is an asbestos-related tumour.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


95. Arrabal-Polo MA, Arias-Santiago SA, Aneiros-Fernandez J, Burkhardt-Perez P, Arrabal-Martin M, Naranjo-Sintes R: Cutaneous metastases in renal cell carcinoma: a case report. Cases J; 2009;2:7948
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal cell carcinoma is the most common form of malignant renal tumour and is extremely lethal.
  • About 25% of the patients develop metastasis at the time of diagnosis, and in many cases during the course of the disease, affecting the lung, lymphatic ganglions, liver, and bone, with skin metastases being quite rare.A 73-year-old patient, who had undergone surgery for adenocarcinoma in the left kidney 10 years previously, visited the dermatological service due to the appearance of recent, rapidly-developing lesion at the back of his neck.
  • A computed tomography scan was performed on the thorax and abdomen, and lesions were observed that were compatible with metastasis in the right kidney and left lung.
  • Urologist should pay attention to cutaneous lesion appearing in these patients as in many times they look like benign lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 1988;114(6):605-12 [3204107.001]
  • [Cites] J Urol. 1994 Dec;152(6 Pt 1):2094-5 [7966685.001]
  • [Cites] Urol Int. 1999;63(3):164-7 [10738187.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):1939-40 [10928130.001]
  • [Cites] Dermatol Online J. 2007;13(4):6 [18319003.001]
  • [Cites] Int J Urol. 2005 Apr;12(4):401-4 [15948730.001]
  • [Cites] Int Semin Surg Oncol. 2006;3:27 [16968548.001]
  • [Cites] J Cutan Pathol. 2007 May;34(5):381-5 [17448192.001]
  • [Cites] Urol Int. 2008;80(1):111-2 [18204246.001]
  • [Cites] Arch Esp Urol. 2005 Apr;58(3):247-50 [15906619.001]
  • (PMID = 19918439.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769389
  •  go-up   go-down


96. Abed R, Grimer RJ, Carter SR, Tillman RM, Abudu A, Jeys L: Soft-tissue metastases: their presentation and origin. J Bone Joint Surg Br; 2009 Aug;91(8):1083-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our aim was to define the clinical features of such patients and to identify the site of their primary tumour.
  • Of 53 patients with a history of malignancy, 52 had metastases from the same primary (lung in 12, melanoma in ten, kidney in nine, gastrointestinal track in four, breast in five, bladder in four, and others in eight).
  • The primary sites in these cases were the lung in 19, gastro-intestinal track in four, kidney in two, melanoma in nine, other in three, and unknown (despite investigations) in ten.
  • There was no correlation between the site of the metastases and the primary tumour.
  • Of these, only 10% had a soft-tissue metastasis, 29% had a benign diagnosis, 55% a soft-tissue sarcoma and 6% another malignancy.
  • [MeSH-major] Kidney Neoplasms / pathology. Lung Neoplasms / pathology. Melanoma / secondary. Skin Neoplasms / pathology. Soft Tissue Neoplasms / secondary. Stomach Neoplasms / pathology


97. Vias M, Massie CE, East P, Scott H, Warren A, Zhou Z, Nikitin AY, Neal DE, Mills IG: Pro-neural transcription factors as cancer markers. BMC Med Genomics; 2008 May 19;1:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aberrant transcription in cancer of genes normally associated with embryonic tissue differentiation at various organ sites may be a hallmark of tumour progression.
  • For example, neuroendocrine differentiation is found more commonly in cancers destined to progress, including prostate and lung.
  • The expression of these pro-neural transcripts effectively segregates metastatic from localised prostate cancer and benign tissue as well as sub-clustering a variety of other human cancers.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2000 Jan 1;20(1):283-93 [10627606.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4411-22 [15304527.001]
  • [Cites] Urology. 2000 Dec 20;56(6):1011-5 [11113749.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):77-84 [15390277.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Clin Lung Cancer. 2005 Jan;6(4):227-36 [15694015.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):343-8 [15925590.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96 [16145049.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):333-8 [1654075.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):313-7 [16818183.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):567-75 [16865272.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Prostate. 2007 Feb 1;67(2):190-202 [17044078.001]
  • [Cites] BMC Bioinformatics. 2007;8:9 [17214880.001]
  • [Cites] Int J Oncol. 2007 Aug;31(2):461-6 [17611704.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):258-62 [1913066.001]
  • [Cites] Hum Pathol. 1987 Feb;18(2):185-94 [3804322.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):345-56 [6203413.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3068-72 [7541709.001]
  • [Cites] Prostate. 1996 Feb;28(2):129-35 [8604394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5355-60 [9144241.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30467-74 [11399758.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):991-1002 [11581320.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Development. 2002 Apr;129(7):1553-67 [11923194.001]
  • [Cites] J Urol. 2002 Sep;168(3):1204-11 [12187268.001]
  • [Cites] Dev Dyn. 2003 Apr;226(4):675-89 [12666205.001]
  • [Cites] Cancer Lett. 2003 Aug 20;198(2):229-39 [12957362.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):943-9 [15010834.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):100-5 [15272537.001]
  • [Cites] Development. 2000 Jul;127(13):2933-43 [10851137.001]
  • (PMID = 18489756.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966; United States / NCRR NIH HHS / RR / K26 RR017595; United States / NCI NIH HHS / CA / R01 CA096823; United States / NCI NIH HHS / CA / R56 CA096823
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2413260
  •  go-up   go-down


98. Beckers F, Ludwig C, Cerinza J, Stoelben E: [Pulmonary nodules in underlying malignant diseases--not necessarily metastases of the primary tumour]. Pneumologie; 2009 Dec;63(12):693-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary nodules in underlying malignant diseases--not necessarily metastases of the primary tumour].
  • [Transliterated title] Der pulmonale Rundherd bei maligner Grunderkrankung--nicht zwingend eine Metastase des Primärtumors.
  • BACKGROUND: In this study the histological examination of pulmonary nodules and a comparison of the number of pre-, intra- and post-operative lung metastases in patients with a previous history of malignant disease were assessed.
  • PATIENTS AND METHODS: Between 1998 and 2003 we operated on 276 patients with suspected lung metastases.
  • The histology of the primary tumour, the number of preoperatively diagnosed nodules, the number of lesions removed during surgery and the number of histologically confirmed metastases of 276 patients are presented.
  • In 15.2% the histology of the resected nodules was benign.
  • In 8.6% of the cases the histological examination showed a primary lung cancer in stage I, in 74.4% of the cases the histology confirmed a metastasis of the primary cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19918721.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Yango J, Pieters T, Coche E, Lambert M: [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir; 2008 Jan;25(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Elévation du CA 19.9 sérique et bronchectasies.
  • However, serum CA 19.9 can be raised in several non-neoplastic disorders, particularly in various benign pulmonary diseases.
  • Exhaustive investigation and clinical evolution excluded a neoplastic digestive disorder but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
  • Antibiotic therapy with amoxicillin-clavulanic acid brought about a decrease in the serum CA 19.9 but level of the tumour marker remained abnormal after more than 2 years.
  • CONCLUSION: This case report emphasises the uselessness of tumour markers as screening tests as a serum level of CA 19.9 up to 50 times normal may be found in benign respiratory disorders such as bronchiectasis.
  • [MeSH-major] Bronchiectasis / diagnosis. CA-19-9 Antigen / blood
  • [MeSH-minor] Aged. Biomarkers / blood. Female. Haemophilus Infections / diagnosis. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans

  • Genetic Alliance. consumer health - Bronchiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288056.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


100. Johnson SR: Lymphangioleiomyomatosis. Eur Respir J; 2006 May;27(5):1056-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal manifestations include lymphadenopathy, cystic lymphatic masses (lymphangioleiomyomas), chylous ascites and angiomyolipoma (a benign tumour).
  • Diagnosis is made by a combination of clinical features and computed tomography scanning or, in cases of doubt, lung biopsy.
  • The only treatment for severe LAM is currently lung transplantation.






Advertisement